<?xml version="1.0" encoding="UTF-8" ?><!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
	"http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" >
<html><head><title>Side-by-side differences</title><link rel="stylesheet" type="text/css" href="/archive/history.css" /><link rel="stylesheet" type="text/css" href="/archive/sdiff.css" /><script type="text/javascript" src="/archive/common.js"></script><script type="text/javascript" src="/archive/sdiff.js"></script><style>table.sdiff div.sdl0 { margin-left: 0em; }
table.sdiff div.sdl1 { margin-left: 2em; }
table.sdiff div.sdl2 { margin-left: 4em; }
table.sdiff div.sdl3 { margin-left: 6em; }
table.sdiff div.sdl4 { margin-left: 8em; }
table.sdiff div.sdl5 { margin-left: 10em; }
table.sdiff div.sdl6 { margin-left: 12em; }
table.sdiff div.sdl7 { margin-left: 14em; }
table.sdiff div.sdl8 { margin-left: 16em; }
table.sdiff div.sdl9 { margin-left: 18em; }
table.sdiff div.sdl10 { margin-left: 20em; }
table.sdiff div.sdl11 { margin-left: 22em; }
table.sdiff div.sdl12 { margin-left: 24em; }
table.sdiff div.sdl13 { margin-left: 26em; }
table.sdiff div.sdl14 { margin-left: 28em; }
table.sdiff div.sdl15 { margin-left: 30em; }
table.sdiff div.sdl16 { margin-left: 32em; }
table.sdiff div.sdl17 { margin-left: 34em; }
table.sdiff div.sdl18 { margin-left: 36em; }
table.sdiff div.sdl19 { margin-left: 38em; }
</style></head><body class="sdiff">
<div class="navTop"><table class="navTopTriptych"><tr><td class="navTopTriptychL"><img src="/archive/ctgov_logo_ttl.gif" alt="ClinicalTrials.gov" width="360" height="47" /></td><td class="navTopTriptychC" style="background-image: url(/archive/ctgov_logo_ttm.gif)" /><td class="navTopTriptychR"><img src="/archive/ctgov_logo_ttr.gif" alt="Linking patients to medical research" width="314" height="47" /></td></tr></table></div>
<div id="sdiff-links" class="navLinks" /><div id="navLinks" class="navLinks"><a href="/archive/NCT01661400">&#8592; History of this study</a><a href="http://clinicaltrials.gov/show/NCT01661400">&#8593; Current version of this study</a></div><form><div id="sdiff-js-menu" style="display: none"><div><input type="checkbox" id="sdiff-HideUnch-cb" name="sdiff-HideUnch" value="true" onclick="SDiffUpdateHideUnch(&#39;sdiff-HideUnch-cb&#39;)" /><span class="sdiff-label" onclick="SDiffToggleHideUnch(&#39;sdiff-HideUnch-cb&#39;)"> Hide unchanged portions (except top/bottom lines)</span></div><div><input type="checkbox" id="sdiff-HideNonMain-cb" name="sdiff-HideNonMain" value="true" onclick="SDiffUpdateHideNonMain(&#39;sdiff-HideNonMain-cb&#39;)" /><span class="sdiff-label" onclick="SDiffToggleHideNonMain(&#39;sdiff-HideNonMain-cb&#39;)"> Hide non-essential portions (contact info, locations, etc.)</span></div><div style="display:none"><input type="checkbox" id="sdiff-HideKey-cb" name="sdiff-HideKey" value="true" onclick="SDiffUpdateHideKey(&#39;sdiff-HideKey-cb&#39;)" /><span class="sdiff-label" onclick="SDiffToggleHideKey(&#39;sdiff-HideKey-cb&#39;)"> Hide key</span></div></div><h1>Changes to NCT01661400 on 2013_01_24</h1><div id="sdiff-key"><div id="sdiff-key-mb"><img id="sdiff-key-minmax" onclick="SDiffToggleHideKey(&#39;sdiff-HideKey-cb&#39;)" src="/archive/minmax.gif" alt="[+/-]" width="16" height="16" style="display:none" /><h2>Key</h2></div><img id="sdiff-key-img" src="/archive/sdiff-key.gif" alt="Key" /></div><div class="sdiff-changedesc"><em>Type of info changed: </em>Protocol, Recruitment, Location/Contact, Misc.</div><div class="sdiff-view" id="sdiff-full" style="display: none"><table class="sdiff navLinks"><colgroup><col id="h-col" /><col id="a-col" /><col id="b-col" /></colgroup><tr><th class="sdiff-h" /><th class="sdiff-a"><div class="sdiff-prev"><a href="/archive/NCT01661400/2012_10_29/changes" title="Show changes from prior version to this one"><img src="/archive/prev.gif" alt="[Previous]" width="23" height="19" /></a></div><h2>Before</h2><h3><a href="/archive/NCT01661400/2012_10_29">(Updated 2012_10_29)</a></h3></th><th class="sdiff-b"><div class="sdiff-next"><a href="/archive/NCT01661400/2013_07_29/changes" title="Show changes from this version to next one"><img src="/archive/next.gif" alt="[Next]" width="23" height="19" /></a></div><h2>After</h2><h3><a href="/archive/NCT01661400/2013_01_24">(Updated 2013_01_24)</a></h3></th></tr>
<tr class="sdiff-unc" id="sdiff-chunk-f1"><td class="sdiff-h">1</td>
<td class="sdiff-a"><img id="sdiff-collapse-f0A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f0&#39;)" style="display:none" /><img id="sdiff-collapse-f0A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f0&#39;)" style="display:none" /><div class="sdl0 sds">&lt;clinical_study&gt;</div>
<div id="sdiff-collapse-f0A-cdiv" class="sdiff-collapsed" title="The middle 63 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f0&#39;)" style="display:none"></div><div id="sdiff-collapse-f0A-ediv" class="sdiff-expanded"><div class="sdl1 sds">&lt;study_id&gt;</div>
<div class="sdl2 sds">&lt;org_name&gt;</div>
<div class="sdl3">  WashingtonU</div>
<div class="sdl2 sdz">&lt;/org_name&gt;</div>
<div class="sdl2 sds">&lt;org_full_name&gt;</div>
<div class="sdl3">  Washington University School of Medicine</div>
<div class="sdl2 sdz">&lt;/org_full_name&gt;</div>
<div class="sdl2 sds">&lt;org_study_id&gt;</div>
<div class="sdl3">  201209088</div>
<div class="sdl2 sdz">&lt;/org_study_id&gt;</div>
<div class="sdl2 sds">&lt;nct_id&gt;</div>
<div class="sdl3">  NCT01661400</div>
<div class="sdl2 sdz">&lt;/nct_id&gt;</div>
<div class="sdl1 sdz">&lt;/study_id&gt;</div>
<div class="sdl1 sds">&lt;is_fda_regulated&gt;</div>
<div class="sdl2">  No</div>
<div class="sdl1 sdz">&lt;/is_fda_regulated&gt;</div>
<div class="sdl1 sds">&lt;brief_title&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  Anti-Angiogenic Therapy Post Transplant (ASCR) for Relapsed and Refractory Pediatric Solid Tumors</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/brief_title&gt;</div>
<div class="sdl1 sds">&lt;acronym&gt;</div>
<div class="sdl2">  ASCR</div>
<div class="sdl1 sdz">&lt;/acronym&gt;</div>
<div class="sdl1 sds">&lt;official_title&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  Anti-Angiogenic Therapy After Autologous Stem Cell Rescue (ASCR) for Relapsed and Refractory Pediatric Solid Tumors</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/official_title&gt;</div>
<div class="sdl1 sds">&lt;study_sponsor&gt;</div>
<div class="sdl2 sds">&lt;lead_sponsor&gt;</div>
<div class="sdl3 sds">&lt;agency&gt;</div>
<div class="sdl4">  Washington University School of Medicine</div>
<div class="sdl3 sdz">&lt;/agency&gt;</div>
<div class="sdl2 sdz">&lt;/lead_sponsor&gt;</div>
<div class="sdl1 sdz">&lt;/study_sponsor&gt;</div>
<div class="sdl1 sds">&lt;resp_party&gt;</div>
<div class="sdl2 sds">&lt;resp_party_type&gt;</div>
<div class="sdl3">  Sponsor</div>
<div class="sdl2 sdz">&lt;/resp_party_type&gt;</div>
<div class="sdl1 sdz">&lt;/resp_party&gt;</div>
<div class="sdl1 sds">&lt;oversight_info&gt;</div>
<div class="sdl2 sds">&lt;regulatory_authority&gt;</div>
<div class="sdl3">  United States: Institutional Review Board</div>
<div class="sdl2 sdz">&lt;/regulatory_authority&gt;</div>
<div class="sdl2 sds">&lt;has_dmc&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/has_dmc&gt;</div>
<div class="sdl1 sdz">&lt;/oversight_info&gt;</div>
<div class="sdl1 sds">&lt;brief_summary&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  The purpose of this research study is to determine whether taking either of two low dose drugs that would prevent new blood vessels from growing after stem cell transplant is feasible, and what the side effects of taking each of these drugs after autologous transplant might be.  The reason the investigators are looking at these drugs is because one of the things that allows tumors to grow quickly is their ability to stimulate the growth of new blood vessels.  By suppressing the growth of new blood vessels after stem cell transplant, the investigators hope to prevent the tumors from coming back or continuing to grow.</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/brief_summary&gt;</div>
<div class="sdl1 sds">&lt;detailed_descr&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/detailed_descr&gt;</div>
<div class="sdl1 sds">&lt;status_block&gt;</div>
<div class="sdl2 sds">&lt;status&gt;</div>
<div class="sdl3">  Not yet recruiting</div>
<div class="sdl2 sdz">&lt;/status&gt;</div>
</div><div class="sdl2 sds">&lt;date&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-f0B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f0&#39;)" style="display:none" /><img id="sdiff-collapse-f0B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f0&#39;)" style="display:none" /><div class="sdl0 sds">&lt;clinical_study&gt;</div>
<div id="sdiff-collapse-f0B-cdiv" class="sdiff-collapsed" title="The middle 63 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f0&#39;)" style="display:none"></div><div id="sdiff-collapse-f0B-ediv" class="sdiff-expanded"><div class="sdl1 sds">&lt;study_id&gt;</div>
<div class="sdl2 sds">&lt;org_name&gt;</div>
<div class="sdl3">  WashingtonU</div>
<div class="sdl2 sdz">&lt;/org_name&gt;</div>
<div class="sdl2 sds">&lt;org_full_name&gt;</div>
<div class="sdl3">  Washington University School of Medicine</div>
<div class="sdl2 sdz">&lt;/org_full_name&gt;</div>
<div class="sdl2 sds">&lt;org_study_id&gt;</div>
<div class="sdl3">  201209088</div>
<div class="sdl2 sdz">&lt;/org_study_id&gt;</div>
<div class="sdl2 sds">&lt;nct_id&gt;</div>
<div class="sdl3">  NCT01661400</div>
<div class="sdl2 sdz">&lt;/nct_id&gt;</div>
<div class="sdl1 sdz">&lt;/study_id&gt;</div>
<div class="sdl1 sds">&lt;is_fda_regulated&gt;</div>
<div class="sdl2">  No</div>
<div class="sdl1 sdz">&lt;/is_fda_regulated&gt;</div>
<div class="sdl1 sds">&lt;brief_title&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  Anti-Angiogenic Therapy Post Transplant (ASCR) for Relapsed and Refractory Pediatric Solid Tumors</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/brief_title&gt;</div>
<div class="sdl1 sds">&lt;acronym&gt;</div>
<div class="sdl2">  ASCR</div>
<div class="sdl1 sdz">&lt;/acronym&gt;</div>
<div class="sdl1 sds">&lt;official_title&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  Anti-Angiogenic Therapy After Autologous Stem Cell Rescue (ASCR) for Relapsed and Refractory Pediatric Solid Tumors</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/official_title&gt;</div>
<div class="sdl1 sds">&lt;study_sponsor&gt;</div>
<div class="sdl2 sds">&lt;lead_sponsor&gt;</div>
<div class="sdl3 sds">&lt;agency&gt;</div>
<div class="sdl4">  Washington University School of Medicine</div>
<div class="sdl3 sdz">&lt;/agency&gt;</div>
<div class="sdl2 sdz">&lt;/lead_sponsor&gt;</div>
<div class="sdl1 sdz">&lt;/study_sponsor&gt;</div>
<div class="sdl1 sds">&lt;resp_party&gt;</div>
<div class="sdl2 sds">&lt;resp_party_type&gt;</div>
<div class="sdl3">  Sponsor</div>
<div class="sdl2 sdz">&lt;/resp_party_type&gt;</div>
<div class="sdl1 sdz">&lt;/resp_party&gt;</div>
<div class="sdl1 sds">&lt;oversight_info&gt;</div>
<div class="sdl2 sds">&lt;regulatory_authority&gt;</div>
<div class="sdl3">  United States: Institutional Review Board</div>
<div class="sdl2 sdz">&lt;/regulatory_authority&gt;</div>
<div class="sdl2 sds">&lt;has_dmc&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/has_dmc&gt;</div>
<div class="sdl1 sdz">&lt;/oversight_info&gt;</div>
<div class="sdl1 sds">&lt;brief_summary&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  The purpose of this research study is to determine whether taking either of two low dose drugs that would prevent new blood vessels from growing after stem cell transplant is feasible, and what the side effects of taking each of these drugs after autologous transplant might be.  The reason the investigators are looking at these drugs is because one of the things that allows tumors to grow quickly is their ability to stimulate the growth of new blood vessels.  By suppressing the growth of new blood vessels after stem cell transplant, the investigators hope to prevent the tumors from coming back or continuing to grow.</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/brief_summary&gt;</div>
<div class="sdl1 sds">&lt;detailed_descr&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/detailed_descr&gt;</div>
<div class="sdl1 sds">&lt;status_block&gt;</div>
<div class="sdl2 sds">&lt;status&gt;</div>
<div class="sdl3">  Not yet recruiting</div>
<div class="sdl2 sdz">&lt;/status&gt;</div>
</div><div class="sdl2 sds">&lt;date&gt;</div>
</td>
</tr>
<tr class="sdiff-chg" id="sdiff-chunk-f2"><td class="sdiff-h">2</td>
<td class="sdiff-a"><div class="sdl3"><span class="sdwc">2012-10</span> </div>
</td>
<td class="sdiff-b"><div class="sdl3"><span class="sdwc">2013-01</span> </div>
</td>
</tr>
<tr class="sdiff-unc" id="sdiff-chunk-f3"><td class="sdiff-h">3</td>
<td class="sdiff-a"><img id="sdiff-collapse-f66A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f66&#39;)" style="display:none" /><img id="sdiff-collapse-f66A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f66&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/date&gt;</div>
<div id="sdiff-collapse-f66A-cdiv" class="sdiff-collapsed" title="The middle 2 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f66&#39;)" style="display:none"></div><div id="sdiff-collapse-f66A-ediv" class="sdiff-expanded"><div class="sdl1 sdz">&lt;/status_block&gt;</div>
<div class="sdl1 sds">&lt;start_date&gt;</div>
</div><div class="sdl2 sds">&lt;date&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-f66B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f66&#39;)" style="display:none" /><img id="sdiff-collapse-f66B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f66&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/date&gt;</div>
<div id="sdiff-collapse-f66B-cdiv" class="sdiff-collapsed" title="The middle 2 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f66&#39;)" style="display:none"></div><div id="sdiff-collapse-f66B-ediv" class="sdiff-expanded"><div class="sdl1 sdz">&lt;/status_block&gt;</div>
<div class="sdl1 sds">&lt;start_date&gt;</div>
</div><div class="sdl2 sds">&lt;date&gt;</div>
</td>
</tr>
<tr class="sdiff-chg" id="sdiff-chunk-f4"><td class="sdiff-h">4</td>
<td class="sdiff-a"><div class="sdl3"><span class="sdwc">2012-11</span> </div>
</td>
<td class="sdiff-b"><div class="sdl3"><span class="sdwc">2013-02</span> </div>
</td>
</tr>
<tr class="sdiff-unc" id="sdiff-chunk-f5"><td class="sdiff-h">5</td>
<td class="sdiff-a"><img id="sdiff-collapse-f71A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f71&#39;)" style="display:none" /><img id="sdiff-collapse-f71A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f71&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/date&gt;</div>
<div id="sdiff-collapse-f71A-cdiv" class="sdiff-collapsed" title="The middle 4 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f71&#39;)" style="display:none"></div><div id="sdiff-collapse-f71A-ediv" class="sdiff-expanded"><div class="sdl1 sdz">&lt;/start_date&gt;</div>
<div class="sdl1 sda">&lt;last_follow_up_date</div>
<div class="sdl1"> type=&quot;Anticipated&quot;</div>
<div class="sdl1">&gt;</div>
</div><div class="sdl2 sds">&lt;date&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-f71B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f71&#39;)" style="display:none" /><img id="sdiff-collapse-f71B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f71&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/date&gt;</div>
<div id="sdiff-collapse-f71B-cdiv" class="sdiff-collapsed" title="The middle 4 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f71&#39;)" style="display:none"></div><div id="sdiff-collapse-f71B-ediv" class="sdiff-expanded"><div class="sdl1 sdz">&lt;/start_date&gt;</div>
<div class="sdl1 sda">&lt;last_follow_up_date</div>
<div class="sdl1"> type=&quot;Anticipated&quot;</div>
<div class="sdl1">&gt;</div>
</div><div class="sdl2 sds">&lt;date&gt;</div>
</td>
</tr>
<tr class="sdiff-chg" id="sdiff-chunk-f6"><td class="sdiff-h">6</td>
<td class="sdiff-a"><div class="sdl3"><span class="sdwc">2019-11</span> </div>
</td>
<td class="sdiff-b"><div class="sdl3"><span class="sdwc">2020-02</span> </div>
</td>
</tr>
<tr class="sdiff-unc" id="sdiff-chunk-f7"><td class="sdiff-h">7</td>
<td class="sdiff-a"><img id="sdiff-collapse-f78A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f78&#39;)" style="display:none" /><img id="sdiff-collapse-f78A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f78&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/date&gt;</div>
<div id="sdiff-collapse-f78A-cdiv" class="sdiff-collapsed" title="The middle 4 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f78&#39;)" style="display:none"></div><div id="sdiff-collapse-f78A-ediv" class="sdiff-expanded"><div class="sdl1 sdz">&lt;/last_follow_up_date&gt;</div>
<div class="sdl1 sda">&lt;primary_compl_date</div>
<div class="sdl1"> type=&quot;Anticipated&quot;</div>
<div class="sdl1">&gt;</div>
</div><div class="sdl2 sds">&lt;date&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-f78B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f78&#39;)" style="display:none" /><img id="sdiff-collapse-f78B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f78&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/date&gt;</div>
<div id="sdiff-collapse-f78B-cdiv" class="sdiff-collapsed" title="The middle 4 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f78&#39;)" style="display:none"></div><div id="sdiff-collapse-f78B-ediv" class="sdiff-expanded"><div class="sdl1 sdz">&lt;/last_follow_up_date&gt;</div>
<div class="sdl1 sda">&lt;primary_compl_date</div>
<div class="sdl1"> type=&quot;Anticipated&quot;</div>
<div class="sdl1">&gt;</div>
</div><div class="sdl2 sds">&lt;date&gt;</div>
</td>
</tr>
<tr class="sdiff-chg" id="sdiff-chunk-f8"><td class="sdiff-h">8</td>
<td class="sdiff-a"><div class="sdl3"><span class="sdwc">2014-11</span> </div>
</td>
<td class="sdiff-b"><div class="sdl3"><span class="sdwc">2015-02</span> </div>
</td>
</tr>
<tr class="sdiff-unc" id="sdiff-chunk-f9"><td class="sdiff-h">9</td>
<td class="sdiff-a"><img id="sdiff-collapse-f85A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f85&#39;)" style="display:none" /><img id="sdiff-collapse-f85A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f85&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/date&gt;</div>
<div id="sdiff-collapse-f85A-cdiv" class="sdiff-collapsed" title="The middle 47 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f85&#39;)" style="display:none"></div><div id="sdiff-collapse-f85A-ediv" class="sdiff-expanded"><div class="sdl1 sdz">&lt;/primary_compl_date&gt;</div>
<div class="sdl1 sds">&lt;phase_block&gt;</div>
<div class="sdl2 sds">&lt;phase&gt;</div>
<div class="sdl3">  N/A</div>
<div class="sdl2 sdz">&lt;/phase&gt;</div>
<div class="sdl1 sdz">&lt;/phase_block&gt;</div>
<div class="sdl1 sds">&lt;study_type&gt;</div>
<div class="sdl2">  Interventional</div>
<div class="sdl1 sdz">&lt;/study_type&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Treatment</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Non-Randomized</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Open Label</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Parallel Assignment</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Safety/Efficacy Study</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;number_of_arms&gt;</div>
<div class="sdl2">  3</div>
<div class="sdl1 sdz">&lt;/number_of_arms&gt;</div>
<div class="sdl1 sds">&lt;primary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Safety</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  30 days</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Measured by absence of grade 4 or 5 non-hematological or grade 5 hematological toxicity from baseline to Day +30</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  Yes</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/primary_outcome&gt;</div>
<div class="sdl1 sds">&lt;primary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Toxicity</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
</div><div class="sdl2 sds">&lt;time_frame&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-f85B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f85&#39;)" style="display:none" /><img id="sdiff-collapse-f85B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f85&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/date&gt;</div>
<div id="sdiff-collapse-f85B-cdiv" class="sdiff-collapsed" title="The middle 47 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f85&#39;)" style="display:none"></div><div id="sdiff-collapse-f85B-ediv" class="sdiff-expanded"><div class="sdl1 sdz">&lt;/primary_compl_date&gt;</div>
<div class="sdl1 sds">&lt;phase_block&gt;</div>
<div class="sdl2 sds">&lt;phase&gt;</div>
<div class="sdl3">  N/A</div>
<div class="sdl2 sdz">&lt;/phase&gt;</div>
<div class="sdl1 sdz">&lt;/phase_block&gt;</div>
<div class="sdl1 sds">&lt;study_type&gt;</div>
<div class="sdl2">  Interventional</div>
<div class="sdl1 sdz">&lt;/study_type&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Treatment</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Non-Randomized</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Open Label</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Parallel Assignment</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Safety/Efficacy Study</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;number_of_arms&gt;</div>
<div class="sdl2">  3</div>
<div class="sdl1 sdz">&lt;/number_of_arms&gt;</div>
<div class="sdl1 sds">&lt;primary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Safety</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  30 days</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Measured by absence of grade 4 or 5 non-hematological or grade 5 hematological toxicity from baseline to Day +30</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  Yes</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/primary_outcome&gt;</div>
<div class="sdl1 sds">&lt;primary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Toxicity</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
</div><div class="sdl2 sds">&lt;time_frame&gt;</div>
</td>
</tr>
<tr class="sdiff-chg" id="sdiff-chunk-f10"><td class="sdiff-h">10</td>
<td class="sdiff-a"><div class="sdl3"><span class="sdwc">30</span> days </div>
</td>
<td class="sdiff-b"><div class="sdl3"><span class="sdwc">90</span> days  </div>
</td>
</tr>
<tr class="sdiff-unc" id="sdiff-chunk-f11"><td class="sdiff-h">11</td>
<td class="sdiff-a"><img id="sdiff-collapse-f135A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f135&#39;)" style="display:none" /><img id="sdiff-collapse-f135A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f135&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div id="sdiff-collapse-f135A-cdiv" class="sdiff-collapsed" title="The middle 21 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f135&#39;)" style="display:none"></div><div id="sdiff-collapse-f135A-ediv" class="sdiff-expanded"><div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Measured by absence of grade 4 or 5 non-hematological or grade 5 hematological toxicity from baseline to Day +30</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  Yes</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/primary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Radiographic marker of neovascularization</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  86 days</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Measurement of anti-angiogenic activity in the treatment of solid tumors from baseline to Day +86.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
</div><div class="sdl2 sds">&lt;safety_issue&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-f135B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f135&#39;)" style="display:none" /><img id="sdiff-collapse-f135B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f135&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div id="sdiff-collapse-f135B-cdiv" class="sdiff-collapsed" title="The middle 21 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f135&#39;)" style="display:none"></div><div id="sdiff-collapse-f135B-ediv" class="sdiff-expanded"><div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Measured by absence of grade 4 or 5 non-hematological or grade 5 hematological toxicity from baseline to Day +30</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  Yes</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/primary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Radiographic marker of neovascularization</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  86 days</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Measurement of anti-angiogenic activity in the treatment of solid tumors from baseline to Day +86.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
</div><div class="sdl2 sds">&lt;safety_issue&gt;</div>
</td>
</tr>
<tr class="sdiff-del" id="sdiff-chunk-f12"><td class="sdiff-h">12</td>
<td class="sdiff-a"><div class="sdl3">  Yes</div>
</td>
<td class="sdiff-b"><div class="sdl3"></div>
</td>
</tr>
<tr class="sdiff-add" id="sdiff-chunk-f13"><td class="sdiff-h">13</td>
<td class="sdiff-a"><div class="sdl3"></div>
<div class="sdl3"></div>
<div class="sdl3"></div>
<div class="sdl3"></div>
<div class="sdl3"></div>
<div class="sdl3"></div>
<div class="sdl3"></div>
<div class="sdl3"></div>
<div class="sdl3"></div>
<div class="sdl3"></div>
<div class="sdl3"></div>
<div class="sdl3"></div>
<div class="sdl3"></div>
<div class="sdl3"></div>
<div class="sdl3"></div>
<div class="sdl3"></div>
<div class="sdl3"></div>
</td>
<td class="sdiff-b"><div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Best overall response</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  86 days</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) guideline version 1.1.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  No</div>
</td>
</tr>
<tr class="sdiff-unc" id="sdiff-chunk-f14"><td class="sdiff-h">14</td>
<td class="sdiff-a"><img id="sdiff-collapse-f176A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f176&#39;)" style="display:none" /><img id="sdiff-collapse-f176A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f176&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div id="sdiff-collapse-f176A-cdiv" class="sdiff-collapsed" title="The middle 232 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f176&#39;)" style="display:none"></div><div id="sdiff-collapse-f176A-ediv" class="sdiff-expanded"><div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sda">&lt;enrollment</div>
<div class="sdl1"> type=&quot;Anticipated&quot;</div>
<div class="sdl1">&gt;</div>
<div class="sdl2">  18</div>
<div class="sdl1 sdz">&lt;/enrollment&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Glioma</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Neuroectodermal Tumors, Primitive</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Wilms Tumor</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Rhabdomyosarcoma</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Sarcoma, Ewing</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Osteosarcoma</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Retinoblastoma</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;arm_group&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  Control</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;arm_type&gt;</div>
<div class="sdl3">  Other</div>
<div class="sdl2 sdz">&lt;/arm_type&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl1 sdz">&lt;/arm_group&gt;</div>
<div class="sdl1 sds">&lt;arm_group&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  Metronomic Cyclophosphamide</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;arm_type&gt;</div>
<div class="sdl3">  Experimental</div>
<div class="sdl2 sdz">&lt;/arm_type&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Cyclophosphamide will be given PO once daily at 2.5 mg/kg/day for children &amp;lt; 40kg or 100 mg daily for children &amp;gt; 40kg beginning Day + 30 (30 days post transplant) and continue until at least Day +86</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl1 sdz">&lt;/arm_group&gt;</div>
<div class="sdl1 sds">&lt;arm_group&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  Thalidomide</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;arm_type&gt;</div>
<div class="sdl3">  Experimental</div>
<div class="sdl2 sdz">&lt;/arm_type&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Thalidomide will be initiated at 3mg/kg PO daily beginning Day + 30 (30 days post transplant) and continue until Day +86</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl1 sdz">&lt;/arm_group&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Other</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  Control</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  No active intervention</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  Control</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Drug</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  Metronomic Cyclophosphamide</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  Metronomic Cyclophosphamide</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  Cytoxan&amp;#174;</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  CPM</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Drug</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  Thalomide</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  Thalidomide</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  Thalomid&amp;#174;</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;eligibility&gt;</div>
<div class="sdl2 sds">&lt;criteria&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Inclusion Criteria:</div>
<div class="sdl4">  </div>
<div class="sdl4">  -Patient must have an original diagnosis confirmed by biopsy* of high-grade glial tumor, low-grade glial tumor, ependymoma, medulloblastoma, primitive neuro-ectodermal tumor (PNET), Wilms&amp;apos; tumor, rhabdomyosarcoma, Ewing&amp;apos;s sarcoma, osteosarcoma, retinoblastoma, or miscellaneous poor-prognosis solid tumors.  Lymphomas and other lymphoid malignancies will not be studied in this protocol.  </div>
<div class="sdl4">  </div>
<div class="sdl4">  * Brain stem glioma patients who have progressed after radiation therapy do not require histologic confirmation. Brain stem gliomas are defined as intrinsic tumors of the pons causing diffuse enlargement.  These patients are diagnosed on clinical and radiographic appearance of the lesion and the biopsy requirement will be waived for this group.</div>
<div class="sdl4">  </div>
<div class="sdl4">  -Patient must have pathologic or imaging confirmation of tumor progression or recurrence within 4 weeks prior to enrollment.</div>
<div class="sdl4">  </div>
<div class="sdl4">  -Patient must be &amp;#8805; 5 years of age and &amp;#8804; 21 years of age at the time of study entry.</div>
<div class="sdl4">  </div>
<div class="sdl4">  -Patient must have a Karnofsky performance status or Lansky* play status &amp;#8805; 50   </div>
<div class="sdl4">  </div>
<div class="sdl4">  * For purpose of determining performance scores, wheelchair-bound patients will be considered ambulatory.</div>
<div class="sdl4">  </div>
<div class="sdl4">  -Patient must have an adequate supply of stem cells for transplant harvested prior to study enrollment, with adequate supply defined as 3 x 106 CD34+ cells/kg for peripheral blood stem cells (PBSC).  Cell mobilization method will be left up to the treating physician&amp;apos;s discretion and may include mobilization growth factor alone or mobilization after chemotherapy.  If patient is unable to mobilize the proper amount of peripheral stem cells, bone marrow may be harvested as the source of hematopoietic stem cells.  In this instance, 3 x 108 mononuclear cells/kg will be considered adequate.  If necessary, a combination of peripheral stem cells and bone marrow can be used.</div>
<div class="sdl4">  </div>
<div class="sdl4">  -Prior radiation therapy and/or chemotherapy, including cyclophosphamide, are permitted.</div>
<div class="sdl4">  </div>
<div class="sdl4">  -Prior anti-angiogenic therapy, including thalidomide and oral cyclophosphamide, is permitted.</div>
<div class="sdl4">  </div>
<div class="sdl4">  -If on corticosteroids for mass effect and/or edema related to the tumor, patient must be on a stable dose for at least 2 weeks prior to study entry.</div>
<div class="sdl4">  </div>
<div class="sdl4">  -Patient must have a life expectancy &amp;gt; 2 months. </div>
<div class="sdl4">  </div>
<div class="sdl4">  -Patient must have an adequate bone marrow reserve as defined by:</div>
<div class="sdl4">  -Hemoglobin &amp;#8805; 9.0 g/dl and</div>
<div class="sdl4">  -Platelet count &amp;#8805; 30,000/ mm3 (transfusion independent) and</div>
<div class="sdl4">  -Peripheral absolute neutrophil count (ANC) &amp;#8805; 750/mm3</div>
<div class="sdl4">   </div>
<div class="sdl4">  -Patient must have adequate cardiac function tested within 4 weeks of study enrollment as defined by:  </div>
<div class="sdl4">  -Shortening fraction of &amp;#8805; 27% by echocardiogram or</div>
<div class="sdl4">  -Ejection fraction of &amp;#8805; 50% by radionuclide angiogram</div>
<div class="sdl4">  </div>
<div class="sdl4">  -Patient must have adequate pulmonary function tested within 4 weeks of study enrollment as defined by:</div>
<div class="sdl4">  -Pulse oximetry &amp;gt; 94% on room air or O2 by nasal cannula and</div>
<div class="sdl4">  -No evidence of dyspnea at rest.</div>
<div class="sdl4">    </div>
<div class="sdl4">  -Patient must have adequate hepatic function as defined by:</div>
<div class="sdl4">  -Total bilirubin &amp;#8804; 1.5x upper limit of normal (ULN) for age and</div>
<div class="sdl4">  -SGOT (AST) or SGPT (ALT) &amp;#8804; 2.5 x ULN (SGOT &amp;#8804; 4x ULN if on Zantac)</div>
<div class="sdl4">  </div>
<div class="sdl4">  -Patient must have adequate renal function as defined by:</div>
<div class="sdl4">  -Serum creatinine &amp;lt; 1.5 mg/dl </div>
<div class="sdl4">  -Glomerular filtration rate (GFR), calculated via I-125 iothalamate clearance, 24-hour creatinine clearance, or Schwartz formula*, &amp;#8805; 70 mL/min and &amp;#8805; 50 mL/min/1.73 m2 done within 4 weeks of study entry </div>
<div class="sdl4">  </div>
<div class="sdl4">  * The Schwartz formula is an estimated glomerular filtration rate in children based upon serum creatinine and height.  Height (Ht) should be measured in cm and serum creatinine (Cr) in mg/dL.  Proportionality constant (k) is 0.55 for children and adolescent girls and 0.7 for adolescent boys aged 13-21.  This constant is based upon a series of evaluations performed by Schwartz.   Formula:  GFR= (k x Ht)/Cr</div>
<div class="sdl4">  </div>
<div class="sdl4">  -If female of childbearing potential (defined as menstruating or amenorrheic from previous medical treatments), the following guidelines must be adhered to:</div>
<div class="sdl4">  -If enrolled in Arm III of this study, patient must be registered at the Celgene S.T.E.P.S. &amp;#174; Program.  </div>
<div class="sdl4">  -If enrolled in Arm III of this study, patient must be willing to practice birth control as outlined in the S.T.E.P.S. Program from the beginning of the study until at least 4 weeks following discontinuation of thalidomide therapy.  Two reliable forms of contraception must be used simultaneously unless continuous abstinence from heterosexual sexual contact is chosen.  Contraceptive methods must include at least one highly effective method (e.g. oral contraceptive pills, injections, hormonal patches, IUD, or implants), AND one additional effective barrier method (e.g. latex condom, diaphragm, cervical cap).  If hormonal or IUD contraception is medically contraindicated, another highly effective method or two barrier methods must be used at the same time.</div>
<div class="sdl4">  -Pregnancy surveillance:</div>
<div class="sdl4">  -Patient must have a negative in office pregnancy test sensitive to within 50 mIU/mL (serum or urine) within 24 hours of beginning thalidomide even if continuous abstinence is the preferred method of birth control.</div>
<div class="sdl4">  -A pregnancy test must be performed weekly during the first 4 weeks of therapy and repeated monthly for patients with regular menses or every 2 weeks for patients with irregular menses </div>
<div class="sdl4">  -Negative pregnancy tests are valid for only 7 days.</div>
<div class="sdl4">  -If irregular bleeding or skipped menses, pregnancy test should be performed and pregnancy counseling given.</div>
<div class="sdl4">  -If pregnancy occurs during treatment, thalidomide must be immediately discontinued.  Any suspected lethal exposure must be reported immediately to Celgene Customer Care Center at 1-888-423-5346, and the patient referred to an OB/GYN experienced in reproductive toxicity for further evaluation and counseling.</div>
<div class="sdl4">  </div>
<div class="sdl4">  -Patient (or legally authorized representative) must be able to understand and willing to sign a written informed consent document.</div>
<div class="sdl4">  </div>
<div class="sdl4">  </div>
<div class="sdl4">  Exclusion Criteria:</div>
<div class="sdl4">  </div>
<div class="sdl4">  -Patient must not have any active, uncontrolled cardiac, hepatic, renal, or psychiatric disease defined as &amp;#8805; grade 3 based on NCI Common Terminology Criteria for Adverse Events v4.0 (CTCAE).</div>
<div class="sdl4">  </div>
<div class="sdl4">  -Patient must not be receiving any other investigational agents.</div>
<div class="sdl4">  </div>
<div class="sdl4">  -Patient must not have any active infection or concurrent illness obscuring toxicity or dangerously altering drug metabolism.</div>
<div class="sdl4">  </div>
<div class="sdl4">  -Patient must not have any thromboembolic event (deep vein thrombosis or pulmonary embolism) less than 3 weeks prior to enrollment.</div>
<div class="sdl4">  </div>
<div class="sdl4">  -Patient must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to any of the agents used in the study.</div>
<div class="sdl4">  </div>
<div class="sdl4">  -Patient must not be pregnant or breastfeeding.</div>
<div class="sdl4">  </div>
<div class="sdl4">  Inclusion of Women and Minorities </div>
<div class="sdl4">  </div>
<div class="sdl4">  -Both men and women and members of all races and ethnic groups are eligible for this trial.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/criteria&gt;</div>
<div class="sdl2 sds">&lt;healthy_volunteers&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/healthy_volunteers&gt;</div>
<div class="sdl2 sds">&lt;gender&gt;</div>
<div class="sdl3">  Both</div>
<div class="sdl2 sdz">&lt;/gender&gt;</div>
<div class="sdl2 sds">&lt;minimum_age&gt;</div>
<div class="sdl3">  5 Years</div>
<div class="sdl2 sdz">&lt;/minimum_age&gt;</div>
<div class="sdl2 sds">&lt;maximum_age&gt;</div>
<div class="sdl3">  21 Years</div>
<div class="sdl2 sdz">&lt;/maximum_age&gt;</div>
<div class="sdl1 sdz">&lt;/eligibility&gt;</div>
<div class="sdl1 sds">&lt;investigator&gt;</div>
<div class="sdl2 sds">&lt;role&gt;</div>
<div class="sdl3">  Principal Investigator</div>
<div class="sdl2 sdz">&lt;/role&gt;</div>
<div class="sdl2 sds">&lt;name&gt;</div>
<div class="sdl3">  Lisa Madden, M.D.</div>
<div class="sdl2 sdz">&lt;/name&gt;</div>
<div class="sdl2 sds">&lt;affiliation&gt;</div>
<div class="sdl3 sds">&lt;agency&gt;</div>
<div class="sdl4">  Washington University School of Medicine</div>
<div class="sdl3 sdz">&lt;/agency&gt;</div>
<div class="sdl2 sdz">&lt;/affiliation&gt;</div>
<div class="sdl1 sdz">&lt;/investigator&gt;</div>
<div class="sdl1 sds">&lt;contact&gt;</div>
<div class="sdl2 sds">&lt;name&gt;</div>
<div class="sdl3">  Lisa Madden, M.D.</div>
<div class="sdl2 sdz">&lt;/name&gt;</div>
</div><div class="sdl2 sds">&lt;phone&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-f176B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f176&#39;)" style="display:none" /><img id="sdiff-collapse-f176B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f176&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div id="sdiff-collapse-f176B-cdiv" class="sdiff-collapsed" title="The middle 232 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f176&#39;)" style="display:none"></div><div id="sdiff-collapse-f176B-ediv" class="sdiff-expanded"><div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sda">&lt;enrollment</div>
<div class="sdl1"> type=&quot;Anticipated&quot;</div>
<div class="sdl1">&gt;</div>
<div class="sdl2">  18</div>
<div class="sdl1 sdz">&lt;/enrollment&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Glioma</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Neuroectodermal Tumors, Primitive</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Wilms Tumor</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Rhabdomyosarcoma</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Sarcoma, Ewing</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Osteosarcoma</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Retinoblastoma</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;arm_group&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  Control</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;arm_type&gt;</div>
<div class="sdl3">  Other</div>
<div class="sdl2 sdz">&lt;/arm_type&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl1 sdz">&lt;/arm_group&gt;</div>
<div class="sdl1 sds">&lt;arm_group&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  Metronomic Cyclophosphamide</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;arm_type&gt;</div>
<div class="sdl3">  Experimental</div>
<div class="sdl2 sdz">&lt;/arm_type&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Cyclophosphamide will be given PO once daily at 2.5 mg/kg/day for children &amp;lt; 40kg or 100 mg daily for children &amp;gt; 40kg beginning Day + 30 (30 days post transplant) and continue until at least Day +86</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl1 sdz">&lt;/arm_group&gt;</div>
<div class="sdl1 sds">&lt;arm_group&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  Thalidomide</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;arm_type&gt;</div>
<div class="sdl3">  Experimental</div>
<div class="sdl2 sdz">&lt;/arm_type&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Thalidomide will be initiated at 3mg/kg PO daily beginning Day + 30 (30 days post transplant) and continue until Day +86</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl1 sdz">&lt;/arm_group&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Other</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  Control</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  No active intervention</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  Control</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Drug</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  Metronomic Cyclophosphamide</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  Metronomic Cyclophosphamide</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  Cytoxan&amp;#174;</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  CPM</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Drug</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  Thalomide</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  Thalidomide</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  Thalomid&amp;#174;</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;eligibility&gt;</div>
<div class="sdl2 sds">&lt;criteria&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Inclusion Criteria:</div>
<div class="sdl4">  </div>
<div class="sdl4">  -Patient must have an original diagnosis confirmed by biopsy* of high-grade glial tumor, low-grade glial tumor, ependymoma, medulloblastoma, primitive neuro-ectodermal tumor (PNET), Wilms&amp;apos; tumor, rhabdomyosarcoma, Ewing&amp;apos;s sarcoma, osteosarcoma, retinoblastoma, or miscellaneous poor-prognosis solid tumors.  Lymphomas and other lymphoid malignancies will not be studied in this protocol.  </div>
<div class="sdl4">  </div>
<div class="sdl4">  * Brain stem glioma patients who have progressed after radiation therapy do not require histologic confirmation. Brain stem gliomas are defined as intrinsic tumors of the pons causing diffuse enlargement.  These patients are diagnosed on clinical and radiographic appearance of the lesion and the biopsy requirement will be waived for this group.</div>
<div class="sdl4">  </div>
<div class="sdl4">  -Patient must have pathologic or imaging confirmation of tumor progression or recurrence within 4 weeks prior to enrollment.</div>
<div class="sdl4">  </div>
<div class="sdl4">  -Patient must be &amp;#8805; 5 years of age and &amp;#8804; 21 years of age at the time of study entry.</div>
<div class="sdl4">  </div>
<div class="sdl4">  -Patient must have a Karnofsky performance status or Lansky* play status &amp;#8805; 50   </div>
<div class="sdl4">  </div>
<div class="sdl4">  * For purpose of determining performance scores, wheelchair-bound patients will be considered ambulatory.</div>
<div class="sdl4">  </div>
<div class="sdl4">  -Patient must have an adequate supply of stem cells for transplant harvested prior to study enrollment, with adequate supply defined as 3 x 106 CD34+ cells/kg for peripheral blood stem cells (PBSC).  Cell mobilization method will be left up to the treating physician&amp;apos;s discretion and may include mobilization growth factor alone or mobilization after chemotherapy.  If patient is unable to mobilize the proper amount of peripheral stem cells, bone marrow may be harvested as the source of hematopoietic stem cells.  In this instance, 3 x 108 mononuclear cells/kg will be considered adequate.  If necessary, a combination of peripheral stem cells and bone marrow can be used.</div>
<div class="sdl4">  </div>
<div class="sdl4">  -Prior radiation therapy and/or chemotherapy, including cyclophosphamide, are permitted.</div>
<div class="sdl4">  </div>
<div class="sdl4">  -Prior anti-angiogenic therapy, including thalidomide and oral cyclophosphamide, is permitted.</div>
<div class="sdl4">  </div>
<div class="sdl4">  -If on corticosteroids for mass effect and/or edema related to the tumor, patient must be on a stable dose for at least 2 weeks prior to study entry.</div>
<div class="sdl4">  </div>
<div class="sdl4">  -Patient must have a life expectancy &amp;gt; 2 months. </div>
<div class="sdl4">  </div>
<div class="sdl4">  -Patient must have an adequate bone marrow reserve as defined by:</div>
<div class="sdl4">  -Hemoglobin &amp;#8805; 9.0 g/dl and</div>
<div class="sdl4">  -Platelet count &amp;#8805; 30,000/ mm3 (transfusion independent) and</div>
<div class="sdl4">  -Peripheral absolute neutrophil count (ANC) &amp;#8805; 750/mm3</div>
<div class="sdl4">   </div>
<div class="sdl4">  -Patient must have adequate cardiac function tested within 4 weeks of study enrollment as defined by:  </div>
<div class="sdl4">  -Shortening fraction of &amp;#8805; 27% by echocardiogram or</div>
<div class="sdl4">  -Ejection fraction of &amp;#8805; 50% by radionuclide angiogram</div>
<div class="sdl4">  </div>
<div class="sdl4">  -Patient must have adequate pulmonary function tested within 4 weeks of study enrollment as defined by:</div>
<div class="sdl4">  -Pulse oximetry &amp;gt; 94% on room air or O2 by nasal cannula and</div>
<div class="sdl4">  -No evidence of dyspnea at rest.</div>
<div class="sdl4">    </div>
<div class="sdl4">  -Patient must have adequate hepatic function as defined by:</div>
<div class="sdl4">  -Total bilirubin &amp;#8804; 1.5x upper limit of normal (ULN) for age and</div>
<div class="sdl4">  -SGOT (AST) or SGPT (ALT) &amp;#8804; 2.5 x ULN (SGOT &amp;#8804; 4x ULN if on Zantac)</div>
<div class="sdl4">  </div>
<div class="sdl4">  -Patient must have adequate renal function as defined by:</div>
<div class="sdl4">  -Serum creatinine &amp;lt; 1.5 mg/dl </div>
<div class="sdl4">  -Glomerular filtration rate (GFR), calculated via I-125 iothalamate clearance, 24-hour creatinine clearance, or Schwartz formula*, &amp;#8805; 70 mL/min and &amp;#8805; 50 mL/min/1.73 m2 done within 4 weeks of study entry </div>
<div class="sdl4">  </div>
<div class="sdl4">  * The Schwartz formula is an estimated glomerular filtration rate in children based upon serum creatinine and height.  Height (Ht) should be measured in cm and serum creatinine (Cr) in mg/dL.  Proportionality constant (k) is 0.55 for children and adolescent girls and 0.7 for adolescent boys aged 13-21.  This constant is based upon a series of evaluations performed by Schwartz.   Formula:  GFR= (k x Ht)/Cr</div>
<div class="sdl4">  </div>
<div class="sdl4">  -If female of childbearing potential (defined as menstruating or amenorrheic from previous medical treatments), the following guidelines must be adhered to:</div>
<div class="sdl4">  -If enrolled in Arm III of this study, patient must be registered at the Celgene S.T.E.P.S. &amp;#174; Program.  </div>
<div class="sdl4">  -If enrolled in Arm III of this study, patient must be willing to practice birth control as outlined in the S.T.E.P.S. Program from the beginning of the study until at least 4 weeks following discontinuation of thalidomide therapy.  Two reliable forms of contraception must be used simultaneously unless continuous abstinence from heterosexual sexual contact is chosen.  Contraceptive methods must include at least one highly effective method (e.g. oral contraceptive pills, injections, hormonal patches, IUD, or implants), AND one additional effective barrier method (e.g. latex condom, diaphragm, cervical cap).  If hormonal or IUD contraception is medically contraindicated, another highly effective method or two barrier methods must be used at the same time.</div>
<div class="sdl4">  -Pregnancy surveillance:</div>
<div class="sdl4">  -Patient must have a negative in office pregnancy test sensitive to within 50 mIU/mL (serum or urine) within 24 hours of beginning thalidomide even if continuous abstinence is the preferred method of birth control.</div>
<div class="sdl4">  -A pregnancy test must be performed weekly during the first 4 weeks of therapy and repeated monthly for patients with regular menses or every 2 weeks for patients with irregular menses </div>
<div class="sdl4">  -Negative pregnancy tests are valid for only 7 days.</div>
<div class="sdl4">  -If irregular bleeding or skipped menses, pregnancy test should be performed and pregnancy counseling given.</div>
<div class="sdl4">  -If pregnancy occurs during treatment, thalidomide must be immediately discontinued.  Any suspected lethal exposure must be reported immediately to Celgene Customer Care Center at 1-888-423-5346, and the patient referred to an OB/GYN experienced in reproductive toxicity for further evaluation and counseling.</div>
<div class="sdl4">  </div>
<div class="sdl4">  -Patient (or legally authorized representative) must be able to understand and willing to sign a written informed consent document.</div>
<div class="sdl4">  </div>
<div class="sdl4">  </div>
<div class="sdl4">  Exclusion Criteria:</div>
<div class="sdl4">  </div>
<div class="sdl4">  -Patient must not have any active, uncontrolled cardiac, hepatic, renal, or psychiatric disease defined as &amp;#8805; grade 3 based on NCI Common Terminology Criteria for Adverse Events v4.0 (CTCAE).</div>
<div class="sdl4">  </div>
<div class="sdl4">  -Patient must not be receiving any other investigational agents.</div>
<div class="sdl4">  </div>
<div class="sdl4">  -Patient must not have any active infection or concurrent illness obscuring toxicity or dangerously altering drug metabolism.</div>
<div class="sdl4">  </div>
<div class="sdl4">  -Patient must not have any thromboembolic event (deep vein thrombosis or pulmonary embolism) less than 3 weeks prior to enrollment.</div>
<div class="sdl4">  </div>
<div class="sdl4">  -Patient must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to any of the agents used in the study.</div>
<div class="sdl4">  </div>
<div class="sdl4">  -Patient must not be pregnant or breastfeeding.</div>
<div class="sdl4">  </div>
<div class="sdl4">  Inclusion of Women and Minorities </div>
<div class="sdl4">  </div>
<div class="sdl4">  -Both men and women and members of all races and ethnic groups are eligible for this trial.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/criteria&gt;</div>
<div class="sdl2 sds">&lt;healthy_volunteers&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/healthy_volunteers&gt;</div>
<div class="sdl2 sds">&lt;gender&gt;</div>
<div class="sdl3">  Both</div>
<div class="sdl2 sdz">&lt;/gender&gt;</div>
<div class="sdl2 sds">&lt;minimum_age&gt;</div>
<div class="sdl3">  5 Years</div>
<div class="sdl2 sdz">&lt;/minimum_age&gt;</div>
<div class="sdl2 sds">&lt;maximum_age&gt;</div>
<div class="sdl3">  21 Years</div>
<div class="sdl2 sdz">&lt;/maximum_age&gt;</div>
<div class="sdl1 sdz">&lt;/eligibility&gt;</div>
<div class="sdl1 sds">&lt;investigator&gt;</div>
<div class="sdl2 sds">&lt;role&gt;</div>
<div class="sdl3">  Principal Investigator</div>
<div class="sdl2 sdz">&lt;/role&gt;</div>
<div class="sdl2 sds">&lt;name&gt;</div>
<div class="sdl3">  Lisa Madden, M.D.</div>
<div class="sdl2 sdz">&lt;/name&gt;</div>
<div class="sdl2 sds">&lt;affiliation&gt;</div>
<div class="sdl3 sds">&lt;agency&gt;</div>
<div class="sdl4">  Washington University School of Medicine</div>
<div class="sdl3 sdz">&lt;/agency&gt;</div>
<div class="sdl2 sdz">&lt;/affiliation&gt;</div>
<div class="sdl1 sdz">&lt;/investigator&gt;</div>
<div class="sdl1 sds">&lt;contact&gt;</div>
<div class="sdl2 sds">&lt;name&gt;</div>
<div class="sdl3">  Lisa Madden, M.D.</div>
<div class="sdl2 sdz">&lt;/name&gt;</div>
</div><div class="sdl2 sds">&lt;phone&gt;</div>
</td>
</tr>
<tr class="sdiff-chg" id="sdiff-chunk-f15"><td class="sdiff-h">15</td>
<td class="sdiff-a"><div class="sdl3"><span class="sdwc">314454-6018</span> </div>
</td>
<td class="sdiff-b"><div class="sdl3"><span class="sdwc">314-454-6018</span> </div>
</td>
</tr>
<tr class="sdiff-unc" id="sdiff-chunk-f16"><td class="sdiff-h">16</td>
<td class="sdiff-a"><img id="sdiff-collapse-f411A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f411&#39;)" style="display:none" /><img id="sdiff-collapse-f411A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f411&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/phone&gt;</div>
<div id="sdiff-collapse-f411A-cdiv" class="sdiff-collapsed" title="The middle 107 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f411&#39;)" style="display:none"></div><div id="sdiff-collapse-f411A-ediv" class="sdiff-expanded"><div class="sdl2 sds">&lt;phone_ext&gt;</div>
<div class="sdl2 sdz">&lt;/phone_ext&gt;</div>
<div class="sdl2 sds">&lt;email&gt;</div>
<div class="sdl3">  madden_l@kids.wustl.edu</div>
<div class="sdl2 sdz">&lt;/email&gt;</div>
<div class="sdl1 sdz">&lt;/contact&gt;</div>
<div class="sdl1 sds">&lt;location&gt;</div>
<div class="sdl2 sds">&lt;facility&gt;</div>
<div class="sdl3 sds">&lt;name&gt;</div>
<div class="sdl4">  Washington University School of Medicine</div>
<div class="sdl3 sdz">&lt;/name&gt;</div>
<div class="sdl3 sds">&lt;address&gt;</div>
<div class="sdl4 sds">&lt;city&gt;</div>
<div class="sdl5">  St. Louis</div>
<div class="sdl4 sdz">&lt;/city&gt;</div>
<div class="sdl4 sds">&lt;state&gt;</div>
<div class="sdl5">  Missouri</div>
<div class="sdl4 sdz">&lt;/state&gt;</div>
<div class="sdl4 sds">&lt;zip&gt;</div>
<div class="sdl5">  63122</div>
<div class="sdl4 sdz">&lt;/zip&gt;</div>
<div class="sdl4 sds">&lt;country&gt;</div>
<div class="sdl5">  United States</div>
<div class="sdl4 sdz">&lt;/country&gt;</div>
<div class="sdl3 sdz">&lt;/address&gt;</div>
<div class="sdl2 sdz">&lt;/facility&gt;</div>
<div class="sdl2 sds">&lt;status&gt;</div>
<div class="sdl3">  Not yet recruiting</div>
<div class="sdl2 sdz">&lt;/status&gt;</div>
<div class="sdl2 sds">&lt;contact&gt;</div>
<div class="sdl3 sds">&lt;name&gt;</div>
<div class="sdl4">  Lisa Madden, M.D.</div>
<div class="sdl3 sdz">&lt;/name&gt;</div>
<div class="sdl3 sds">&lt;phone&gt;</div>
<div class="sdl4">  314-454-6018</div>
<div class="sdl3 sdz">&lt;/phone&gt;</div>
<div class="sdl3 sds">&lt;phone_ext&gt;</div>
<div class="sdl3 sdz">&lt;/phone_ext&gt;</div>
<div class="sdl3 sds">&lt;email&gt;</div>
<div class="sdl4">  madden_l@kids.wustl.edu</div>
<div class="sdl3 sdz">&lt;/email&gt;</div>
<div class="sdl2 sdz">&lt;/contact&gt;</div>
<div class="sdl2 sds">&lt;contact&gt;</div>
<div class="sdl3 sds">&lt;role&gt;</div>
<div class="sdl4">  Sub-Investigator</div>
<div class="sdl3 sdz">&lt;/role&gt;</div>
<div class="sdl3 sds">&lt;name&gt;</div>
<div class="sdl4">  Robert Hayashi, M.D.</div>
<div class="sdl3 sdz">&lt;/name&gt;</div>
<div class="sdl2 sdz">&lt;/contact&gt;</div>
<div class="sdl2 sds">&lt;contact&gt;</div>
<div class="sdl3 sds">&lt;role&gt;</div>
<div class="sdl4">  Sub-Investigator</div>
<div class="sdl3 sdz">&lt;/role&gt;</div>
<div class="sdl3 sds">&lt;name&gt;</div>
<div class="sdl4">  Shalini Shenoy, M.D.</div>
<div class="sdl3 sdz">&lt;/name&gt;</div>
<div class="sdl2 sdz">&lt;/contact&gt;</div>
<div class="sdl2 sds">&lt;contact&gt;</div>
<div class="sdl3 sds">&lt;role&gt;</div>
<div class="sdl4">  Sub-Investigator</div>
<div class="sdl3 sdz">&lt;/role&gt;</div>
<div class="sdl3 sds">&lt;name&gt;</div>
<div class="sdl4">  Jeffrey Bednarski, M.D.</div>
<div class="sdl3 sdz">&lt;/name&gt;</div>
<div class="sdl2 sdz">&lt;/contact&gt;</div>
<div class="sdl2 sds">&lt;contact&gt;</div>
<div class="sdl3 sds">&lt;role&gt;</div>
<div class="sdl4">  Sub-Investigator</div>
<div class="sdl3 sdz">&lt;/role&gt;</div>
<div class="sdl3 sds">&lt;name&gt;</div>
<div class="sdl4">  Monica Hente, ARNP</div>
<div class="sdl3 sdz">&lt;/name&gt;</div>
<div class="sdl2 sdz">&lt;/contact&gt;</div>
<div class="sdl2 sds">&lt;contact&gt;</div>
<div class="sdl3 sds">&lt;role&gt;</div>
<div class="sdl4">  Sub-Investigator</div>
<div class="sdl3 sdz">&lt;/role&gt;</div>
<div class="sdl3 sds">&lt;name&gt;</div>
<div class="sdl4">  Geetika Khanna, M.D.</div>
<div class="sdl3 sdz">&lt;/name&gt;</div>
<div class="sdl2 sdz">&lt;/contact&gt;</div>
<div class="sdl2 sds">&lt;contact&gt;</div>
<div class="sdl3 sds">&lt;role&gt;</div>
<div class="sdl4">  Sub-Investigator</div>
<div class="sdl3 sdz">&lt;/role&gt;</div>
<div class="sdl3 sds">&lt;name&gt;</div>
<div class="sdl4">  Joshua Shimony, Ph.D.</div>
<div class="sdl3 sdz">&lt;/name&gt;</div>
<div class="sdl2 sdz">&lt;/contact&gt;</div>
<div class="sdl1 sdz">&lt;/location&gt;</div>
<div class="sdl1 sds">&lt;see_also&gt;</div>
<div class="sdl2 sds">&lt;annotation&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/annotation&gt;</div>
<div class="sdl2 sds">&lt;url&gt;</div>
<div class="sdl3">  http://www.siteman.wustl.edu</div>
<div class="sdl2 sdz">&lt;/url&gt;</div>
<div class="sdl1 sdz">&lt;/see_also&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Glioma includes ependymoma and medulloblastoma</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;initial_release_date&gt;</div>
<div class="sdl2">  2012-07-30</div>
<div class="sdl1 sdz">&lt;/initial_release_date&gt;</div>
</div><div class="sdl1 sds">&lt;last_release_date&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-f411B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f411&#39;)" style="display:none" /><img id="sdiff-collapse-f411B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f411&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/phone&gt;</div>
<div id="sdiff-collapse-f411B-cdiv" class="sdiff-collapsed" title="The middle 107 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f411&#39;)" style="display:none"></div><div id="sdiff-collapse-f411B-ediv" class="sdiff-expanded"><div class="sdl2 sds">&lt;phone_ext&gt;</div>
<div class="sdl2 sdz">&lt;/phone_ext&gt;</div>
<div class="sdl2 sds">&lt;email&gt;</div>
<div class="sdl3">  madden_l@kids.wustl.edu</div>
<div class="sdl2 sdz">&lt;/email&gt;</div>
<div class="sdl1 sdz">&lt;/contact&gt;</div>
<div class="sdl1 sds">&lt;location&gt;</div>
<div class="sdl2 sds">&lt;facility&gt;</div>
<div class="sdl3 sds">&lt;name&gt;</div>
<div class="sdl4">  Washington University School of Medicine</div>
<div class="sdl3 sdz">&lt;/name&gt;</div>
<div class="sdl3 sds">&lt;address&gt;</div>
<div class="sdl4 sds">&lt;city&gt;</div>
<div class="sdl5">  St. Louis</div>
<div class="sdl4 sdz">&lt;/city&gt;</div>
<div class="sdl4 sds">&lt;state&gt;</div>
<div class="sdl5">  Missouri</div>
<div class="sdl4 sdz">&lt;/state&gt;</div>
<div class="sdl4 sds">&lt;zip&gt;</div>
<div class="sdl5">  63122</div>
<div class="sdl4 sdz">&lt;/zip&gt;</div>
<div class="sdl4 sds">&lt;country&gt;</div>
<div class="sdl5">  United States</div>
<div class="sdl4 sdz">&lt;/country&gt;</div>
<div class="sdl3 sdz">&lt;/address&gt;</div>
<div class="sdl2 sdz">&lt;/facility&gt;</div>
<div class="sdl2 sds">&lt;status&gt;</div>
<div class="sdl3">  Not yet recruiting</div>
<div class="sdl2 sdz">&lt;/status&gt;</div>
<div class="sdl2 sds">&lt;contact&gt;</div>
<div class="sdl3 sds">&lt;name&gt;</div>
<div class="sdl4">  Lisa Madden, M.D.</div>
<div class="sdl3 sdz">&lt;/name&gt;</div>
<div class="sdl3 sds">&lt;phone&gt;</div>
<div class="sdl4">  314-454-6018</div>
<div class="sdl3 sdz">&lt;/phone&gt;</div>
<div class="sdl3 sds">&lt;phone_ext&gt;</div>
<div class="sdl3 sdz">&lt;/phone_ext&gt;</div>
<div class="sdl3 sds">&lt;email&gt;</div>
<div class="sdl4">  madden_l@kids.wustl.edu</div>
<div class="sdl3 sdz">&lt;/email&gt;</div>
<div class="sdl2 sdz">&lt;/contact&gt;</div>
<div class="sdl2 sds">&lt;contact&gt;</div>
<div class="sdl3 sds">&lt;role&gt;</div>
<div class="sdl4">  Sub-Investigator</div>
<div class="sdl3 sdz">&lt;/role&gt;</div>
<div class="sdl3 sds">&lt;name&gt;</div>
<div class="sdl4">  Robert Hayashi, M.D.</div>
<div class="sdl3 sdz">&lt;/name&gt;</div>
<div class="sdl2 sdz">&lt;/contact&gt;</div>
<div class="sdl2 sds">&lt;contact&gt;</div>
<div class="sdl3 sds">&lt;role&gt;</div>
<div class="sdl4">  Sub-Investigator</div>
<div class="sdl3 sdz">&lt;/role&gt;</div>
<div class="sdl3 sds">&lt;name&gt;</div>
<div class="sdl4">  Shalini Shenoy, M.D.</div>
<div class="sdl3 sdz">&lt;/name&gt;</div>
<div class="sdl2 sdz">&lt;/contact&gt;</div>
<div class="sdl2 sds">&lt;contact&gt;</div>
<div class="sdl3 sds">&lt;role&gt;</div>
<div class="sdl4">  Sub-Investigator</div>
<div class="sdl3 sdz">&lt;/role&gt;</div>
<div class="sdl3 sds">&lt;name&gt;</div>
<div class="sdl4">  Jeffrey Bednarski, M.D.</div>
<div class="sdl3 sdz">&lt;/name&gt;</div>
<div class="sdl2 sdz">&lt;/contact&gt;</div>
<div class="sdl2 sds">&lt;contact&gt;</div>
<div class="sdl3 sds">&lt;role&gt;</div>
<div class="sdl4">  Sub-Investigator</div>
<div class="sdl3 sdz">&lt;/role&gt;</div>
<div class="sdl3 sds">&lt;name&gt;</div>
<div class="sdl4">  Monica Hente, ARNP</div>
<div class="sdl3 sdz">&lt;/name&gt;</div>
<div class="sdl2 sdz">&lt;/contact&gt;</div>
<div class="sdl2 sds">&lt;contact&gt;</div>
<div class="sdl3 sds">&lt;role&gt;</div>
<div class="sdl4">  Sub-Investigator</div>
<div class="sdl3 sdz">&lt;/role&gt;</div>
<div class="sdl3 sds">&lt;name&gt;</div>
<div class="sdl4">  Geetika Khanna, M.D.</div>
<div class="sdl3 sdz">&lt;/name&gt;</div>
<div class="sdl2 sdz">&lt;/contact&gt;</div>
<div class="sdl2 sds">&lt;contact&gt;</div>
<div class="sdl3 sds">&lt;role&gt;</div>
<div class="sdl4">  Sub-Investigator</div>
<div class="sdl3 sdz">&lt;/role&gt;</div>
<div class="sdl3 sds">&lt;name&gt;</div>
<div class="sdl4">  Joshua Shimony, Ph.D.</div>
<div class="sdl3 sdz">&lt;/name&gt;</div>
<div class="sdl2 sdz">&lt;/contact&gt;</div>
<div class="sdl1 sdz">&lt;/location&gt;</div>
<div class="sdl1 sds">&lt;see_also&gt;</div>
<div class="sdl2 sds">&lt;annotation&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/annotation&gt;</div>
<div class="sdl2 sds">&lt;url&gt;</div>
<div class="sdl3">  http://www.siteman.wustl.edu</div>
<div class="sdl2 sdz">&lt;/url&gt;</div>
<div class="sdl1 sdz">&lt;/see_also&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Glioma includes ependymoma and medulloblastoma</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;initial_release_date&gt;</div>
<div class="sdl2">  2012-07-30</div>
<div class="sdl1 sdz">&lt;/initial_release_date&gt;</div>
</div><div class="sdl1 sds">&lt;last_release_date&gt;</div>
</td>
</tr>
<tr class="sdiff-chg" id="sdiff-chunk-f17"><td class="sdiff-h">17</td>
<td class="sdiff-a"><div class="sdl2"><span class="sdwc">2012-10-29</span> </div>
</td>
<td class="sdiff-b"><div class="sdl2"><span class="sdwc">2013-01-24</span> </div>
</td>
</tr>
<tr class="sdiff-unc" id="sdiff-chunk-f18"><td class="sdiff-h">18</td>
<td class="sdiff-a"><img id="sdiff-collapse-f521A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f521&#39;)" style="display:none" /><img id="sdiff-collapse-f521A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f521&#39;)" style="display:none" /><div class="sdl1 sdz">&lt;/last_release_date&gt;</div>
<div id="sdiff-collapse-f521A-cdiv" class="sdiff-collapsed" title="The middle 4 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f521&#39;)" style="display:none"></div><div id="sdiff-collapse-f521A-ediv" class="sdiff-expanded"><div class="sdl1 sds">&lt;init_disposition_release_date&gt;</div>
<div class="sdl1 sdz">&lt;/init_disposition_release_date&gt;</div>
<div class="sdl1 sds">&lt;init_results_release_date&gt;</div>
<div class="sdl1 sdz">&lt;/init_results_release_date&gt;</div>
</div><div class="sdl0 sdz">&lt;/clinical_study&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-f521B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-f521&#39;)" style="display:none" /><img id="sdiff-collapse-f521B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f521&#39;)" style="display:none" /><div class="sdl1 sdz">&lt;/last_release_date&gt;</div>
<div id="sdiff-collapse-f521B-cdiv" class="sdiff-collapsed" title="The middle 4 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-f521&#39;)" style="display:none"></div><div id="sdiff-collapse-f521B-ediv" class="sdiff-expanded"><div class="sdl1 sds">&lt;init_disposition_release_date&gt;</div>
<div class="sdl1 sdz">&lt;/init_disposition_release_date&gt;</div>
<div class="sdl1 sds">&lt;init_results_release_date&gt;</div>
<div class="sdl1 sdz">&lt;/init_results_release_date&gt;</div>
</div><div class="sdl0 sdz">&lt;/clinical_study&gt;</div>
</td>
</tr>

</table></div><div class="sdiff-view" id="sdiff-main" style="display: block"><table class="sdiff navLinks"><colgroup><col id="h-col" /><col id="a-col" /><col id="b-col" /></colgroup><tr><th class="sdiff-h" /><th class="sdiff-a"><div class="sdiff-prev"><a href="/archive/NCT01661400/2012_10_29/changes" title="Show changes from prior version to this one"><img src="/archive/prev.gif" alt="[Previous]" width="23" height="19" /></a></div><h2>Before</h2><h3><a href="/archive/NCT01661400/2012_10_29">(Updated 2012_10_29)</a></h3></th><th class="sdiff-b"><div class="sdiff-next"><a href="/archive/NCT01661400/2013_07_29/changes" title="Show changes from this version to next one"><img src="/archive/next.gif" alt="[Next]" width="23" height="19" /></a></div><h2>After</h2><h3><a href="/archive/NCT01661400/2013_01_24">(Updated 2013_01_24)</a></h3></th></tr>
<tr class="sdiff-unc" id="sdiff-chunk-m1"><td class="sdiff-h">1</td>
<td class="sdiff-a"><img id="sdiff-collapse-m0A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-m0&#39;)" style="display:none" /><img id="sdiff-collapse-m0A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m0&#39;)" style="display:none" /><div class="sdl0 sds">&lt;clinical_study&gt;</div>
<div id="sdiff-collapse-m0A-cdiv" class="sdiff-collapsed" title="The middle 63 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m0&#39;)" style="display:none"></div><div id="sdiff-collapse-m0A-ediv" class="sdiff-expanded"><div class="sdl1 sds">&lt;study_id&gt;</div>
<div class="sdl2 sds">&lt;org_name&gt;</div>
<div class="sdl3">  WashingtonU</div>
<div class="sdl2 sdz">&lt;/org_name&gt;</div>
<div class="sdl2 sds">&lt;org_full_name&gt;</div>
<div class="sdl3">  Washington University School of Medicine</div>
<div class="sdl2 sdz">&lt;/org_full_name&gt;</div>
<div class="sdl2 sds">&lt;org_study_id&gt;</div>
<div class="sdl3">  201209088</div>
<div class="sdl2 sdz">&lt;/org_study_id&gt;</div>
<div class="sdl2 sds">&lt;nct_id&gt;</div>
<div class="sdl3">  NCT01661400</div>
<div class="sdl2 sdz">&lt;/nct_id&gt;</div>
<div class="sdl1 sdz">&lt;/study_id&gt;</div>
<div class="sdl1 sds">&lt;is_fda_regulated&gt;</div>
<div class="sdl2">  No</div>
<div class="sdl1 sdz">&lt;/is_fda_regulated&gt;</div>
<div class="sdl1 sds">&lt;brief_title&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  Anti-Angiogenic Therapy Post Transplant (ASCR) for Relapsed and Refractory Pediatric Solid Tumors</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/brief_title&gt;</div>
<div class="sdl1 sds">&lt;acronym&gt;</div>
<div class="sdl2">  ASCR</div>
<div class="sdl1 sdz">&lt;/acronym&gt;</div>
<div class="sdl1 sds">&lt;official_title&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  Anti-Angiogenic Therapy After Autologous Stem Cell Rescue (ASCR) for Relapsed and Refractory Pediatric Solid Tumors</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/official_title&gt;</div>
<div class="sdl1 sds">&lt;study_sponsor&gt;</div>
<div class="sdl2 sds">&lt;lead_sponsor&gt;</div>
<div class="sdl3 sds">&lt;agency&gt;</div>
<div class="sdl4">  Washington University School of Medicine</div>
<div class="sdl3 sdz">&lt;/agency&gt;</div>
<div class="sdl2 sdz">&lt;/lead_sponsor&gt;</div>
<div class="sdl1 sdz">&lt;/study_sponsor&gt;</div>
<div class="sdl1 sds">&lt;resp_party&gt;</div>
<div class="sdl2 sds">&lt;resp_party_type&gt;</div>
<div class="sdl3">  Sponsor</div>
<div class="sdl2 sdz">&lt;/resp_party_type&gt;</div>
<div class="sdl1 sdz">&lt;/resp_party&gt;</div>
<div class="sdl1 sds">&lt;oversight_info&gt;</div>
<div class="sdl2 sds">&lt;regulatory_authority&gt;</div>
<div class="sdl3">  United States: Institutional Review Board</div>
<div class="sdl2 sdz">&lt;/regulatory_authority&gt;</div>
<div class="sdl2 sds">&lt;has_dmc&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/has_dmc&gt;</div>
<div class="sdl1 sdz">&lt;/oversight_info&gt;</div>
<div class="sdl1 sds">&lt;brief_summary&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  The purpose of this research study is to determine whether taking either of two low dose drugs that would prevent new blood vessels from growing after stem cell transplant is feasible, and what the side effects of taking each of these drugs after autologous transplant might be.  The reason the investigators are looking at these drugs is because one of the things that allows tumors to grow quickly is their ability to stimulate the growth of new blood vessels.  By suppressing the growth of new blood vessels after stem cell transplant, the investigators hope to prevent the tumors from coming back or continuing to grow.</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/brief_summary&gt;</div>
<div class="sdl1 sds">&lt;detailed_descr&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/detailed_descr&gt;</div>
<div class="sdl1 sds">&lt;status_block&gt;</div>
<div class="sdl2 sds">&lt;status&gt;</div>
<div class="sdl3">  Not yet recruiting</div>
<div class="sdl2 sdz">&lt;/status&gt;</div>
</div><div class="sdl2 sds">&lt;date&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-m0B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-m0&#39;)" style="display:none" /><img id="sdiff-collapse-m0B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m0&#39;)" style="display:none" /><div class="sdl0 sds">&lt;clinical_study&gt;</div>
<div id="sdiff-collapse-m0B-cdiv" class="sdiff-collapsed" title="The middle 63 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m0&#39;)" style="display:none"></div><div id="sdiff-collapse-m0B-ediv" class="sdiff-expanded"><div class="sdl1 sds">&lt;study_id&gt;</div>
<div class="sdl2 sds">&lt;org_name&gt;</div>
<div class="sdl3">  WashingtonU</div>
<div class="sdl2 sdz">&lt;/org_name&gt;</div>
<div class="sdl2 sds">&lt;org_full_name&gt;</div>
<div class="sdl3">  Washington University School of Medicine</div>
<div class="sdl2 sdz">&lt;/org_full_name&gt;</div>
<div class="sdl2 sds">&lt;org_study_id&gt;</div>
<div class="sdl3">  201209088</div>
<div class="sdl2 sdz">&lt;/org_study_id&gt;</div>
<div class="sdl2 sds">&lt;nct_id&gt;</div>
<div class="sdl3">  NCT01661400</div>
<div class="sdl2 sdz">&lt;/nct_id&gt;</div>
<div class="sdl1 sdz">&lt;/study_id&gt;</div>
<div class="sdl1 sds">&lt;is_fda_regulated&gt;</div>
<div class="sdl2">  No</div>
<div class="sdl1 sdz">&lt;/is_fda_regulated&gt;</div>
<div class="sdl1 sds">&lt;brief_title&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  Anti-Angiogenic Therapy Post Transplant (ASCR) for Relapsed and Refractory Pediatric Solid Tumors</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/brief_title&gt;</div>
<div class="sdl1 sds">&lt;acronym&gt;</div>
<div class="sdl2">  ASCR</div>
<div class="sdl1 sdz">&lt;/acronym&gt;</div>
<div class="sdl1 sds">&lt;official_title&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  Anti-Angiogenic Therapy After Autologous Stem Cell Rescue (ASCR) for Relapsed and Refractory Pediatric Solid Tumors</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/official_title&gt;</div>
<div class="sdl1 sds">&lt;study_sponsor&gt;</div>
<div class="sdl2 sds">&lt;lead_sponsor&gt;</div>
<div class="sdl3 sds">&lt;agency&gt;</div>
<div class="sdl4">  Washington University School of Medicine</div>
<div class="sdl3 sdz">&lt;/agency&gt;</div>
<div class="sdl2 sdz">&lt;/lead_sponsor&gt;</div>
<div class="sdl1 sdz">&lt;/study_sponsor&gt;</div>
<div class="sdl1 sds">&lt;resp_party&gt;</div>
<div class="sdl2 sds">&lt;resp_party_type&gt;</div>
<div class="sdl3">  Sponsor</div>
<div class="sdl2 sdz">&lt;/resp_party_type&gt;</div>
<div class="sdl1 sdz">&lt;/resp_party&gt;</div>
<div class="sdl1 sds">&lt;oversight_info&gt;</div>
<div class="sdl2 sds">&lt;regulatory_authority&gt;</div>
<div class="sdl3">  United States: Institutional Review Board</div>
<div class="sdl2 sdz">&lt;/regulatory_authority&gt;</div>
<div class="sdl2 sds">&lt;has_dmc&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/has_dmc&gt;</div>
<div class="sdl1 sdz">&lt;/oversight_info&gt;</div>
<div class="sdl1 sds">&lt;brief_summary&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl3">  The purpose of this research study is to determine whether taking either of two low dose drugs that would prevent new blood vessels from growing after stem cell transplant is feasible, and what the side effects of taking each of these drugs after autologous transplant might be.  The reason the investigators are looking at these drugs is because one of the things that allows tumors to grow quickly is their ability to stimulate the growth of new blood vessels.  By suppressing the growth of new blood vessels after stem cell transplant, the investigators hope to prevent the tumors from coming back or continuing to grow.</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/brief_summary&gt;</div>
<div class="sdl1 sds">&lt;detailed_descr&gt;</div>
<div class="sdl2 sds">&lt;textblock&gt;</div>
<div class="sdl2 sdz">&lt;/textblock&gt;</div>
<div class="sdl1 sdz">&lt;/detailed_descr&gt;</div>
<div class="sdl1 sds">&lt;status_block&gt;</div>
<div class="sdl2 sds">&lt;status&gt;</div>
<div class="sdl3">  Not yet recruiting</div>
<div class="sdl2 sdz">&lt;/status&gt;</div>
</div><div class="sdl2 sds">&lt;date&gt;</div>
</td>
</tr>
<tr class="sdiff-chg" id="sdiff-chunk-m2"><td class="sdiff-h">2</td>
<td class="sdiff-a"><div class="sdl3"><span class="sdwc">2012-10</span> </div>
</td>
<td class="sdiff-b"><div class="sdl3"><span class="sdwc">2013-01</span> </div>
</td>
</tr>
<tr class="sdiff-unc" id="sdiff-chunk-m3"><td class="sdiff-h">3</td>
<td class="sdiff-a"><img id="sdiff-collapse-m66A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-m66&#39;)" style="display:none" /><img id="sdiff-collapse-m66A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m66&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/date&gt;</div>
<div id="sdiff-collapse-m66A-cdiv" class="sdiff-collapsed" title="The middle 2 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m66&#39;)" style="display:none"></div><div id="sdiff-collapse-m66A-ediv" class="sdiff-expanded"><div class="sdl1 sdz">&lt;/status_block&gt;</div>
<div class="sdl1 sds">&lt;start_date&gt;</div>
</div><div class="sdl2 sds">&lt;date&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-m66B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-m66&#39;)" style="display:none" /><img id="sdiff-collapse-m66B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m66&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/date&gt;</div>
<div id="sdiff-collapse-m66B-cdiv" class="sdiff-collapsed" title="The middle 2 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m66&#39;)" style="display:none"></div><div id="sdiff-collapse-m66B-ediv" class="sdiff-expanded"><div class="sdl1 sdz">&lt;/status_block&gt;</div>
<div class="sdl1 sds">&lt;start_date&gt;</div>
</div><div class="sdl2 sds">&lt;date&gt;</div>
</td>
</tr>
<tr class="sdiff-chg" id="sdiff-chunk-m4"><td class="sdiff-h">4</td>
<td class="sdiff-a"><div class="sdl3"><span class="sdwc">2012-11</span> </div>
</td>
<td class="sdiff-b"><div class="sdl3"><span class="sdwc">2013-02</span> </div>
</td>
</tr>
<tr class="sdiff-unc" id="sdiff-chunk-m5"><td class="sdiff-h">5</td>
<td class="sdiff-a"><img id="sdiff-collapse-m71A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-m71&#39;)" style="display:none" /><img id="sdiff-collapse-m71A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m71&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/date&gt;</div>
<div id="sdiff-collapse-m71A-cdiv" class="sdiff-collapsed" title="The middle 4 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m71&#39;)" style="display:none"></div><div id="sdiff-collapse-m71A-ediv" class="sdiff-expanded"><div class="sdl1 sdz">&lt;/start_date&gt;</div>
<div class="sdl1 sda">&lt;last_follow_up_date</div>
<div class="sdl1"> type=&quot;Anticipated&quot;</div>
<div class="sdl1">&gt;</div>
</div><div class="sdl2 sds">&lt;date&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-m71B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-m71&#39;)" style="display:none" /><img id="sdiff-collapse-m71B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m71&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/date&gt;</div>
<div id="sdiff-collapse-m71B-cdiv" class="sdiff-collapsed" title="The middle 4 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m71&#39;)" style="display:none"></div><div id="sdiff-collapse-m71B-ediv" class="sdiff-expanded"><div class="sdl1 sdz">&lt;/start_date&gt;</div>
<div class="sdl1 sda">&lt;last_follow_up_date</div>
<div class="sdl1"> type=&quot;Anticipated&quot;</div>
<div class="sdl1">&gt;</div>
</div><div class="sdl2 sds">&lt;date&gt;</div>
</td>
</tr>
<tr class="sdiff-chg" id="sdiff-chunk-m6"><td class="sdiff-h">6</td>
<td class="sdiff-a"><div class="sdl3"><span class="sdwc">2019-11</span> </div>
</td>
<td class="sdiff-b"><div class="sdl3"><span class="sdwc">2020-02</span> </div>
</td>
</tr>
<tr class="sdiff-unc" id="sdiff-chunk-m7"><td class="sdiff-h">7</td>
<td class="sdiff-a"><img id="sdiff-collapse-m78A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-m78&#39;)" style="display:none" /><img id="sdiff-collapse-m78A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m78&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/date&gt;</div>
<div id="sdiff-collapse-m78A-cdiv" class="sdiff-collapsed" title="The middle 4 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m78&#39;)" style="display:none"></div><div id="sdiff-collapse-m78A-ediv" class="sdiff-expanded"><div class="sdl1 sdz">&lt;/last_follow_up_date&gt;</div>
<div class="sdl1 sda">&lt;primary_compl_date</div>
<div class="sdl1"> type=&quot;Anticipated&quot;</div>
<div class="sdl1">&gt;</div>
</div><div class="sdl2 sds">&lt;date&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-m78B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-m78&#39;)" style="display:none" /><img id="sdiff-collapse-m78B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m78&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/date&gt;</div>
<div id="sdiff-collapse-m78B-cdiv" class="sdiff-collapsed" title="The middle 4 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m78&#39;)" style="display:none"></div><div id="sdiff-collapse-m78B-ediv" class="sdiff-expanded"><div class="sdl1 sdz">&lt;/last_follow_up_date&gt;</div>
<div class="sdl1 sda">&lt;primary_compl_date</div>
<div class="sdl1"> type=&quot;Anticipated&quot;</div>
<div class="sdl1">&gt;</div>
</div><div class="sdl2 sds">&lt;date&gt;</div>
</td>
</tr>
<tr class="sdiff-chg" id="sdiff-chunk-m8"><td class="sdiff-h">8</td>
<td class="sdiff-a"><div class="sdl3"><span class="sdwc">2014-11</span> </div>
</td>
<td class="sdiff-b"><div class="sdl3"><span class="sdwc">2015-02</span> </div>
</td>
</tr>
<tr class="sdiff-unc" id="sdiff-chunk-m9"><td class="sdiff-h">9</td>
<td class="sdiff-a"><img id="sdiff-collapse-m85A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-m85&#39;)" style="display:none" /><img id="sdiff-collapse-m85A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m85&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/date&gt;</div>
<div id="sdiff-collapse-m85A-cdiv" class="sdiff-collapsed" title="The middle 47 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m85&#39;)" style="display:none"></div><div id="sdiff-collapse-m85A-ediv" class="sdiff-expanded"><div class="sdl1 sdz">&lt;/primary_compl_date&gt;</div>
<div class="sdl1 sds">&lt;phase_block&gt;</div>
<div class="sdl2 sds">&lt;phase&gt;</div>
<div class="sdl3">  N/A</div>
<div class="sdl2 sdz">&lt;/phase&gt;</div>
<div class="sdl1 sdz">&lt;/phase_block&gt;</div>
<div class="sdl1 sds">&lt;study_type&gt;</div>
<div class="sdl2">  Interventional</div>
<div class="sdl1 sdz">&lt;/study_type&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Treatment</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Non-Randomized</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Open Label</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Parallel Assignment</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Safety/Efficacy Study</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;number_of_arms&gt;</div>
<div class="sdl2">  3</div>
<div class="sdl1 sdz">&lt;/number_of_arms&gt;</div>
<div class="sdl1 sds">&lt;primary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Safety</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  30 days</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Measured by absence of grade 4 or 5 non-hematological or grade 5 hematological toxicity from baseline to Day +30</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  Yes</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/primary_outcome&gt;</div>
<div class="sdl1 sds">&lt;primary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Toxicity</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
</div><div class="sdl2 sds">&lt;time_frame&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-m85B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-m85&#39;)" style="display:none" /><img id="sdiff-collapse-m85B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m85&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/date&gt;</div>
<div id="sdiff-collapse-m85B-cdiv" class="sdiff-collapsed" title="The middle 47 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m85&#39;)" style="display:none"></div><div id="sdiff-collapse-m85B-ediv" class="sdiff-expanded"><div class="sdl1 sdz">&lt;/primary_compl_date&gt;</div>
<div class="sdl1 sds">&lt;phase_block&gt;</div>
<div class="sdl2 sds">&lt;phase&gt;</div>
<div class="sdl3">  N/A</div>
<div class="sdl2 sdz">&lt;/phase&gt;</div>
<div class="sdl1 sdz">&lt;/phase_block&gt;</div>
<div class="sdl1 sds">&lt;study_type&gt;</div>
<div class="sdl2">  Interventional</div>
<div class="sdl1 sdz">&lt;/study_type&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Treatment</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Non-Randomized</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Open Label</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Parallel Assignment</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;design&gt;</div>
<div class="sdl2">  Safety/Efficacy Study</div>
<div class="sdl1 sdz">&lt;/design&gt;</div>
<div class="sdl1 sds">&lt;number_of_arms&gt;</div>
<div class="sdl2">  3</div>
<div class="sdl1 sdz">&lt;/number_of_arms&gt;</div>
<div class="sdl1 sds">&lt;primary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Safety</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  30 days</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Measured by absence of grade 4 or 5 non-hematological or grade 5 hematological toxicity from baseline to Day +30</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  Yes</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/primary_outcome&gt;</div>
<div class="sdl1 sds">&lt;primary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Toxicity</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
</div><div class="sdl2 sds">&lt;time_frame&gt;</div>
</td>
</tr>
<tr class="sdiff-chg" id="sdiff-chunk-m10"><td class="sdiff-h">10</td>
<td class="sdiff-a"><div class="sdl3"><span class="sdwc">30</span> days </div>
</td>
<td class="sdiff-b"><div class="sdl3"><span class="sdwc">90</span> days  </div>
</td>
</tr>
<tr class="sdiff-unc" id="sdiff-chunk-m11"><td class="sdiff-h">11</td>
<td class="sdiff-a"><img id="sdiff-collapse-m135A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-m135&#39;)" style="display:none" /><img id="sdiff-collapse-m135A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m135&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div id="sdiff-collapse-m135A-cdiv" class="sdiff-collapsed" title="The middle 21 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m135&#39;)" style="display:none"></div><div id="sdiff-collapse-m135A-ediv" class="sdiff-expanded"><div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Measured by absence of grade 4 or 5 non-hematological or grade 5 hematological toxicity from baseline to Day +30</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  Yes</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/primary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Radiographic marker of neovascularization</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  86 days</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Measurement of anti-angiogenic activity in the treatment of solid tumors from baseline to Day +86.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
</div><div class="sdl2 sds">&lt;safety_issue&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-m135B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-m135&#39;)" style="display:none" /><img id="sdiff-collapse-m135B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m135&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div id="sdiff-collapse-m135B-cdiv" class="sdiff-collapsed" title="The middle 21 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m135&#39;)" style="display:none"></div><div id="sdiff-collapse-m135B-ediv" class="sdiff-expanded"><div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Measured by absence of grade 4 or 5 non-hematological or grade 5 hematological toxicity from baseline to Day +30</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  Yes</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/primary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Radiographic marker of neovascularization</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  86 days</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Measurement of anti-angiogenic activity in the treatment of solid tumors from baseline to Day +86.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
</div><div class="sdl2 sds">&lt;safety_issue&gt;</div>
</td>
</tr>
<tr class="sdiff-del" id="sdiff-chunk-m12"><td class="sdiff-h">12</td>
<td class="sdiff-a"><div class="sdl3">  Yes</div>
</td>
<td class="sdiff-b"><div class="sdl3"></div>
</td>
</tr>
<tr class="sdiff-add" id="sdiff-chunk-m13"><td class="sdiff-h">13</td>
<td class="sdiff-a"><div class="sdl3"></div>
<div class="sdl3"></div>
<div class="sdl3"></div>
<div class="sdl3"></div>
<div class="sdl3"></div>
<div class="sdl3"></div>
<div class="sdl3"></div>
<div class="sdl3"></div>
<div class="sdl3"></div>
<div class="sdl3"></div>
<div class="sdl3"></div>
<div class="sdl3"></div>
<div class="sdl3"></div>
<div class="sdl3"></div>
<div class="sdl3"></div>
<div class="sdl3"></div>
<div class="sdl3"></div>
</td>
<td class="sdiff-b"><div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sds">&lt;secondary_outcome&gt;</div>
<div class="sdl2 sds">&lt;measure&gt;</div>
<div class="sdl3">  Best overall response</div>
<div class="sdl2 sdz">&lt;/measure&gt;</div>
<div class="sdl2 sds">&lt;time_frame&gt;</div>
<div class="sdl3">  86 days</div>
<div class="sdl2 sdz">&lt;/time_frame&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) guideline version 1.1.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;safety_issue&gt;</div>
<div class="sdl3">  No</div>
</td>
</tr>
<tr class="sdiff-unc" id="sdiff-chunk-m14"><td class="sdiff-h">14</td>
<td class="sdiff-a"><img id="sdiff-collapse-m176A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-m176&#39;)" style="display:none" /><img id="sdiff-collapse-m176A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m176&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div id="sdiff-collapse-m176A-cdiv" class="sdiff-collapsed" title="The middle 244 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m176&#39;)" style="display:none"></div><div id="sdiff-collapse-m176A-ediv" class="sdiff-expanded"><div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sda">&lt;enrollment</div>
<div class="sdl1"> type=&quot;Anticipated&quot;</div>
<div class="sdl1">&gt;</div>
<div class="sdl2">  18</div>
<div class="sdl1 sdz">&lt;/enrollment&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Glioma</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Neuroectodermal Tumors, Primitive</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Wilms Tumor</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Rhabdomyosarcoma</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Sarcoma, Ewing</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Osteosarcoma</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Retinoblastoma</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;arm_group&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  Control</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;arm_type&gt;</div>
<div class="sdl3">  Other</div>
<div class="sdl2 sdz">&lt;/arm_type&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl1 sdz">&lt;/arm_group&gt;</div>
<div class="sdl1 sds">&lt;arm_group&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  Metronomic Cyclophosphamide</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;arm_type&gt;</div>
<div class="sdl3">  Experimental</div>
<div class="sdl2 sdz">&lt;/arm_type&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Cyclophosphamide will be given PO once daily at 2.5 mg/kg/day for children &amp;lt; 40kg or 100 mg daily for children &amp;gt; 40kg beginning Day + 30 (30 days post transplant) and continue until at least Day +86</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl1 sdz">&lt;/arm_group&gt;</div>
<div class="sdl1 sds">&lt;arm_group&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  Thalidomide</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;arm_type&gt;</div>
<div class="sdl3">  Experimental</div>
<div class="sdl2 sdz">&lt;/arm_type&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Thalidomide will be initiated at 3mg/kg PO daily beginning Day + 30 (30 days post transplant) and continue until Day +86</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl1 sdz">&lt;/arm_group&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Other</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  Control</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  No active intervention</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  Control</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Drug</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  Metronomic Cyclophosphamide</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  Metronomic Cyclophosphamide</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  Cytoxan&amp;#174;</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  CPM</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Drug</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  Thalomide</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  Thalidomide</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  Thalomid&amp;#174;</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;eligibility&gt;</div>
<div class="sdl2 sds">&lt;criteria&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Inclusion Criteria:</div>
<div class="sdl4">  </div>
<div class="sdl4">  -Patient must have an original diagnosis confirmed by biopsy* of high-grade glial tumor, low-grade glial tumor, ependymoma, medulloblastoma, primitive neuro-ectodermal tumor (PNET), Wilms&amp;apos; tumor, rhabdomyosarcoma, Ewing&amp;apos;s sarcoma, osteosarcoma, retinoblastoma, or miscellaneous poor-prognosis solid tumors.  Lymphomas and other lymphoid malignancies will not be studied in this protocol.  </div>
<div class="sdl4">  </div>
<div class="sdl4">  * Brain stem glioma patients who have progressed after radiation therapy do not require histologic confirmation. Brain stem gliomas are defined as intrinsic tumors of the pons causing diffuse enlargement.  These patients are diagnosed on clinical and radiographic appearance of the lesion and the biopsy requirement will be waived for this group.</div>
<div class="sdl4">  </div>
<div class="sdl4">  -Patient must have pathologic or imaging confirmation of tumor progression or recurrence within 4 weeks prior to enrollment.</div>
<div class="sdl4">  </div>
<div class="sdl4">  -Patient must be &amp;#8805; 5 years of age and &amp;#8804; 21 years of age at the time of study entry.</div>
<div class="sdl4">  </div>
<div class="sdl4">  -Patient must have a Karnofsky performance status or Lansky* play status &amp;#8805; 50   </div>
<div class="sdl4">  </div>
<div class="sdl4">  * For purpose of determining performance scores, wheelchair-bound patients will be considered ambulatory.</div>
<div class="sdl4">  </div>
<div class="sdl4">  -Patient must have an adequate supply of stem cells for transplant harvested prior to study enrollment, with adequate supply defined as 3 x 106 CD34+ cells/kg for peripheral blood stem cells (PBSC).  Cell mobilization method will be left up to the treating physician&amp;apos;s discretion and may include mobilization growth factor alone or mobilization after chemotherapy.  If patient is unable to mobilize the proper amount of peripheral stem cells, bone marrow may be harvested as the source of hematopoietic stem cells.  In this instance, 3 x 108 mononuclear cells/kg will be considered adequate.  If necessary, a combination of peripheral stem cells and bone marrow can be used.</div>
<div class="sdl4">  </div>
<div class="sdl4">  -Prior radiation therapy and/or chemotherapy, including cyclophosphamide, are permitted.</div>
<div class="sdl4">  </div>
<div class="sdl4">  -Prior anti-angiogenic therapy, including thalidomide and oral cyclophosphamide, is permitted.</div>
<div class="sdl4">  </div>
<div class="sdl4">  -If on corticosteroids for mass effect and/or edema related to the tumor, patient must be on a stable dose for at least 2 weeks prior to study entry.</div>
<div class="sdl4">  </div>
<div class="sdl4">  -Patient must have a life expectancy &amp;gt; 2 months. </div>
<div class="sdl4">  </div>
<div class="sdl4">  -Patient must have an adequate bone marrow reserve as defined by:</div>
<div class="sdl4">  -Hemoglobin &amp;#8805; 9.0 g/dl and</div>
<div class="sdl4">  -Platelet count &amp;#8805; 30,000/ mm3 (transfusion independent) and</div>
<div class="sdl4">  -Peripheral absolute neutrophil count (ANC) &amp;#8805; 750/mm3</div>
<div class="sdl4">   </div>
<div class="sdl4">  -Patient must have adequate cardiac function tested within 4 weeks of study enrollment as defined by:  </div>
<div class="sdl4">  -Shortening fraction of &amp;#8805; 27% by echocardiogram or</div>
<div class="sdl4">  -Ejection fraction of &amp;#8805; 50% by radionuclide angiogram</div>
<div class="sdl4">  </div>
<div class="sdl4">  -Patient must have adequate pulmonary function tested within 4 weeks of study enrollment as defined by:</div>
<div class="sdl4">  -Pulse oximetry &amp;gt; 94% on room air or O2 by nasal cannula and</div>
<div class="sdl4">  -No evidence of dyspnea at rest.</div>
<div class="sdl4">    </div>
<div class="sdl4">  -Patient must have adequate hepatic function as defined by:</div>
<div class="sdl4">  -Total bilirubin &amp;#8804; 1.5x upper limit of normal (ULN) for age and</div>
<div class="sdl4">  -SGOT (AST) or SGPT (ALT) &amp;#8804; 2.5 x ULN (SGOT &amp;#8804; 4x ULN if on Zantac)</div>
<div class="sdl4">  </div>
<div class="sdl4">  -Patient must have adequate renal function as defined by:</div>
<div class="sdl4">  -Serum creatinine &amp;lt; 1.5 mg/dl </div>
<div class="sdl4">  -Glomerular filtration rate (GFR), calculated via I-125 iothalamate clearance, 24-hour creatinine clearance, or Schwartz formula*, &amp;#8805; 70 mL/min and &amp;#8805; 50 mL/min/1.73 m2 done within 4 weeks of study entry </div>
<div class="sdl4">  </div>
<div class="sdl4">  * The Schwartz formula is an estimated glomerular filtration rate in children based upon serum creatinine and height.  Height (Ht) should be measured in cm and serum creatinine (Cr) in mg/dL.  Proportionality constant (k) is 0.55 for children and adolescent girls and 0.7 for adolescent boys aged 13-21.  This constant is based upon a series of evaluations performed by Schwartz.   Formula:  GFR= (k x Ht)/Cr</div>
<div class="sdl4">  </div>
<div class="sdl4">  -If female of childbearing potential (defined as menstruating or amenorrheic from previous medical treatments), the following guidelines must be adhered to:</div>
<div class="sdl4">  -If enrolled in Arm III of this study, patient must be registered at the Celgene S.T.E.P.S. &amp;#174; Program.  </div>
<div class="sdl4">  -If enrolled in Arm III of this study, patient must be willing to practice birth control as outlined in the S.T.E.P.S. Program from the beginning of the study until at least 4 weeks following discontinuation of thalidomide therapy.  Two reliable forms of contraception must be used simultaneously unless continuous abstinence from heterosexual sexual contact is chosen.  Contraceptive methods must include at least one highly effective method (e.g. oral contraceptive pills, injections, hormonal patches, IUD, or implants), AND one additional effective barrier method (e.g. latex condom, diaphragm, cervical cap).  If hormonal or IUD contraception is medically contraindicated, another highly effective method or two barrier methods must be used at the same time.</div>
<div class="sdl4">  -Pregnancy surveillance:</div>
<div class="sdl4">  -Patient must have a negative in office pregnancy test sensitive to within 50 mIU/mL (serum or urine) within 24 hours of beginning thalidomide even if continuous abstinence is the preferred method of birth control.</div>
<div class="sdl4">  -A pregnancy test must be performed weekly during the first 4 weeks of therapy and repeated monthly for patients with regular menses or every 2 weeks for patients with irregular menses </div>
<div class="sdl4">  -Negative pregnancy tests are valid for only 7 days.</div>
<div class="sdl4">  -If irregular bleeding or skipped menses, pregnancy test should be performed and pregnancy counseling given.</div>
<div class="sdl4">  -If pregnancy occurs during treatment, thalidomide must be immediately discontinued.  Any suspected lethal exposure must be reported immediately to Celgene Customer Care Center at 1-888-423-5346, and the patient referred to an OB/GYN experienced in reproductive toxicity for further evaluation and counseling.</div>
<div class="sdl4">  </div>
<div class="sdl4">  -Patient (or legally authorized representative) must be able to understand and willing to sign a written informed consent document.</div>
<div class="sdl4">  </div>
<div class="sdl4">  </div>
<div class="sdl4">  Exclusion Criteria:</div>
<div class="sdl4">  </div>
<div class="sdl4">  -Patient must not have any active, uncontrolled cardiac, hepatic, renal, or psychiatric disease defined as &amp;#8805; grade 3 based on NCI Common Terminology Criteria for Adverse Events v4.0 (CTCAE).</div>
<div class="sdl4">  </div>
<div class="sdl4">  -Patient must not be receiving any other investigational agents.</div>
<div class="sdl4">  </div>
<div class="sdl4">  -Patient must not have any active infection or concurrent illness obscuring toxicity or dangerously altering drug metabolism.</div>
<div class="sdl4">  </div>
<div class="sdl4">  -Patient must not have any thromboembolic event (deep vein thrombosis or pulmonary embolism) less than 3 weeks prior to enrollment.</div>
<div class="sdl4">  </div>
<div class="sdl4">  -Patient must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to any of the agents used in the study.</div>
<div class="sdl4">  </div>
<div class="sdl4">  -Patient must not be pregnant or breastfeeding.</div>
<div class="sdl4">  </div>
<div class="sdl4">  Inclusion of Women and Minorities </div>
<div class="sdl4">  </div>
<div class="sdl4">  -Both men and women and members of all races and ethnic groups are eligible for this trial.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/criteria&gt;</div>
<div class="sdl2 sds">&lt;healthy_volunteers&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/healthy_volunteers&gt;</div>
<div class="sdl2 sds">&lt;gender&gt;</div>
<div class="sdl3">  Both</div>
<div class="sdl2 sdz">&lt;/gender&gt;</div>
<div class="sdl2 sds">&lt;minimum_age&gt;</div>
<div class="sdl3">  5 Years</div>
<div class="sdl2 sdz">&lt;/minimum_age&gt;</div>
<div class="sdl2 sds">&lt;maximum_age&gt;</div>
<div class="sdl3">  21 Years</div>
<div class="sdl2 sdz">&lt;/maximum_age&gt;</div>
<div class="sdl1 sdz">&lt;/eligibility&gt;</div>
<div class="sdl1 sds">&lt;investigator&gt;</div>
<div class="sdl2 sds">&lt;role&gt;</div>
<div class="sdl3">  Principal Investigator</div>
<div class="sdl2 sdz">&lt;/role&gt;</div>
<div class="sdl2 sds">&lt;name&gt;</div>
<div class="sdl3">  Lisa Madden, M.D.</div>
<div class="sdl2 sdz">&lt;/name&gt;</div>
<div class="sdl2 sds">&lt;affiliation&gt;</div>
<div class="sdl3 sds">&lt;agency&gt;</div>
<div class="sdl4">  Washington University School of Medicine</div>
<div class="sdl3 sdz">&lt;/agency&gt;</div>
<div class="sdl2 sdz">&lt;/affiliation&gt;</div>
<div class="sdl1 sdz">&lt;/investigator&gt;</div>
<div class="sdl1 sds">&lt;see_also&gt;</div>
<div class="sdl2 sds">&lt;annotation&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/annotation&gt;</div>
<div class="sdl2 sds">&lt;url&gt;</div>
<div class="sdl3">  http://www.siteman.wustl.edu</div>
<div class="sdl2 sdz">&lt;/url&gt;</div>
<div class="sdl1 sdz">&lt;/see_also&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Glioma includes ependymoma and medulloblastoma</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;initial_release_date&gt;</div>
<div class="sdl2">  2012-07-30</div>
<div class="sdl1 sdz">&lt;/initial_release_date&gt;</div>
</div><div class="sdl1 sds">&lt;last_release_date&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-m176B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-m176&#39;)" style="display:none" /><img id="sdiff-collapse-m176B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m176&#39;)" style="display:none" /><div class="sdl2 sdz">&lt;/safety_issue&gt;</div>
<div id="sdiff-collapse-m176B-cdiv" class="sdiff-collapsed" title="The middle 244 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m176&#39;)" style="display:none"></div><div id="sdiff-collapse-m176B-ediv" class="sdiff-expanded"><div class="sdl1 sdz">&lt;/secondary_outcome&gt;</div>
<div class="sdl1 sda">&lt;enrollment</div>
<div class="sdl1"> type=&quot;Anticipated&quot;</div>
<div class="sdl1">&gt;</div>
<div class="sdl2">  18</div>
<div class="sdl1 sdz">&lt;/enrollment&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Glioma</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Neuroectodermal Tumors, Primitive</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Wilms Tumor</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Rhabdomyosarcoma</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Sarcoma, Ewing</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Osteosarcoma</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;condition&gt;</div>
<div class="sdl2">  Retinoblastoma</div>
<div class="sdl1 sdz">&lt;/condition&gt;</div>
<div class="sdl1 sds">&lt;arm_group&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  Control</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;arm_type&gt;</div>
<div class="sdl3">  Other</div>
<div class="sdl2 sdz">&lt;/arm_type&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl1 sdz">&lt;/arm_group&gt;</div>
<div class="sdl1 sds">&lt;arm_group&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  Metronomic Cyclophosphamide</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;arm_type&gt;</div>
<div class="sdl3">  Experimental</div>
<div class="sdl2 sdz">&lt;/arm_type&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Cyclophosphamide will be given PO once daily at 2.5 mg/kg/day for children &amp;lt; 40kg or 100 mg daily for children &amp;gt; 40kg beginning Day + 30 (30 days post transplant) and continue until at least Day +86</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl1 sdz">&lt;/arm_group&gt;</div>
<div class="sdl1 sds">&lt;arm_group&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  Thalidomide</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;arm_type&gt;</div>
<div class="sdl3">  Experimental</div>
<div class="sdl2 sdz">&lt;/arm_type&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Thalidomide will be initiated at 3mg/kg PO daily beginning Day + 30 (30 days post transplant) and continue until Day +86</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl1 sdz">&lt;/arm_group&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Other</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  Control</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  No active intervention</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  Control</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Drug</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  Metronomic Cyclophosphamide</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  Metronomic Cyclophosphamide</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  Cytoxan&amp;#174;</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  CPM</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;intervention&gt;</div>
<div class="sdl2 sds">&lt;intervent_type&gt;</div>
<div class="sdl3">  Drug</div>
<div class="sdl2 sdz">&lt;/intervent_type&gt;</div>
<div class="sdl2 sds">&lt;primary_name&gt;</div>
<div class="sdl3">  Thalomide</div>
<div class="sdl2 sdz">&lt;/primary_name&gt;</div>
<div class="sdl2 sds">&lt;description&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/description&gt;</div>
<div class="sdl2 sds">&lt;arm_group_label&gt;</div>
<div class="sdl3">  Thalidomide</div>
<div class="sdl2 sdz">&lt;/arm_group_label&gt;</div>
<div class="sdl2 sds">&lt;other_name&gt;</div>
<div class="sdl3">  Thalomid&amp;#174;</div>
<div class="sdl2 sdz">&lt;/other_name&gt;</div>
<div class="sdl1 sdz">&lt;/intervention&gt;</div>
<div class="sdl1 sds">&lt;eligibility&gt;</div>
<div class="sdl2 sds">&lt;criteria&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Inclusion Criteria:</div>
<div class="sdl4">  </div>
<div class="sdl4">  -Patient must have an original diagnosis confirmed by biopsy* of high-grade glial tumor, low-grade glial tumor, ependymoma, medulloblastoma, primitive neuro-ectodermal tumor (PNET), Wilms&amp;apos; tumor, rhabdomyosarcoma, Ewing&amp;apos;s sarcoma, osteosarcoma, retinoblastoma, or miscellaneous poor-prognosis solid tumors.  Lymphomas and other lymphoid malignancies will not be studied in this protocol.  </div>
<div class="sdl4">  </div>
<div class="sdl4">  * Brain stem glioma patients who have progressed after radiation therapy do not require histologic confirmation. Brain stem gliomas are defined as intrinsic tumors of the pons causing diffuse enlargement.  These patients are diagnosed on clinical and radiographic appearance of the lesion and the biopsy requirement will be waived for this group.</div>
<div class="sdl4">  </div>
<div class="sdl4">  -Patient must have pathologic or imaging confirmation of tumor progression or recurrence within 4 weeks prior to enrollment.</div>
<div class="sdl4">  </div>
<div class="sdl4">  -Patient must be &amp;#8805; 5 years of age and &amp;#8804; 21 years of age at the time of study entry.</div>
<div class="sdl4">  </div>
<div class="sdl4">  -Patient must have a Karnofsky performance status or Lansky* play status &amp;#8805; 50   </div>
<div class="sdl4">  </div>
<div class="sdl4">  * For purpose of determining performance scores, wheelchair-bound patients will be considered ambulatory.</div>
<div class="sdl4">  </div>
<div class="sdl4">  -Patient must have an adequate supply of stem cells for transplant harvested prior to study enrollment, with adequate supply defined as 3 x 106 CD34+ cells/kg for peripheral blood stem cells (PBSC).  Cell mobilization method will be left up to the treating physician&amp;apos;s discretion and may include mobilization growth factor alone or mobilization after chemotherapy.  If patient is unable to mobilize the proper amount of peripheral stem cells, bone marrow may be harvested as the source of hematopoietic stem cells.  In this instance, 3 x 108 mononuclear cells/kg will be considered adequate.  If necessary, a combination of peripheral stem cells and bone marrow can be used.</div>
<div class="sdl4">  </div>
<div class="sdl4">  -Prior radiation therapy and/or chemotherapy, including cyclophosphamide, are permitted.</div>
<div class="sdl4">  </div>
<div class="sdl4">  -Prior anti-angiogenic therapy, including thalidomide and oral cyclophosphamide, is permitted.</div>
<div class="sdl4">  </div>
<div class="sdl4">  -If on corticosteroids for mass effect and/or edema related to the tumor, patient must be on a stable dose for at least 2 weeks prior to study entry.</div>
<div class="sdl4">  </div>
<div class="sdl4">  -Patient must have a life expectancy &amp;gt; 2 months. </div>
<div class="sdl4">  </div>
<div class="sdl4">  -Patient must have an adequate bone marrow reserve as defined by:</div>
<div class="sdl4">  -Hemoglobin &amp;#8805; 9.0 g/dl and</div>
<div class="sdl4">  -Platelet count &amp;#8805; 30,000/ mm3 (transfusion independent) and</div>
<div class="sdl4">  -Peripheral absolute neutrophil count (ANC) &amp;#8805; 750/mm3</div>
<div class="sdl4">   </div>
<div class="sdl4">  -Patient must have adequate cardiac function tested within 4 weeks of study enrollment as defined by:  </div>
<div class="sdl4">  -Shortening fraction of &amp;#8805; 27% by echocardiogram or</div>
<div class="sdl4">  -Ejection fraction of &amp;#8805; 50% by radionuclide angiogram</div>
<div class="sdl4">  </div>
<div class="sdl4">  -Patient must have adequate pulmonary function tested within 4 weeks of study enrollment as defined by:</div>
<div class="sdl4">  -Pulse oximetry &amp;gt; 94% on room air or O2 by nasal cannula and</div>
<div class="sdl4">  -No evidence of dyspnea at rest.</div>
<div class="sdl4">    </div>
<div class="sdl4">  -Patient must have adequate hepatic function as defined by:</div>
<div class="sdl4">  -Total bilirubin &amp;#8804; 1.5x upper limit of normal (ULN) for age and</div>
<div class="sdl4">  -SGOT (AST) or SGPT (ALT) &amp;#8804; 2.5 x ULN (SGOT &amp;#8804; 4x ULN if on Zantac)</div>
<div class="sdl4">  </div>
<div class="sdl4">  -Patient must have adequate renal function as defined by:</div>
<div class="sdl4">  -Serum creatinine &amp;lt; 1.5 mg/dl </div>
<div class="sdl4">  -Glomerular filtration rate (GFR), calculated via I-125 iothalamate clearance, 24-hour creatinine clearance, or Schwartz formula*, &amp;#8805; 70 mL/min and &amp;#8805; 50 mL/min/1.73 m2 done within 4 weeks of study entry </div>
<div class="sdl4">  </div>
<div class="sdl4">  * The Schwartz formula is an estimated glomerular filtration rate in children based upon serum creatinine and height.  Height (Ht) should be measured in cm and serum creatinine (Cr) in mg/dL.  Proportionality constant (k) is 0.55 for children and adolescent girls and 0.7 for adolescent boys aged 13-21.  This constant is based upon a series of evaluations performed by Schwartz.   Formula:  GFR= (k x Ht)/Cr</div>
<div class="sdl4">  </div>
<div class="sdl4">  -If female of childbearing potential (defined as menstruating or amenorrheic from previous medical treatments), the following guidelines must be adhered to:</div>
<div class="sdl4">  -If enrolled in Arm III of this study, patient must be registered at the Celgene S.T.E.P.S. &amp;#174; Program.  </div>
<div class="sdl4">  -If enrolled in Arm III of this study, patient must be willing to practice birth control as outlined in the S.T.E.P.S. Program from the beginning of the study until at least 4 weeks following discontinuation of thalidomide therapy.  Two reliable forms of contraception must be used simultaneously unless continuous abstinence from heterosexual sexual contact is chosen.  Contraceptive methods must include at least one highly effective method (e.g. oral contraceptive pills, injections, hormonal patches, IUD, or implants), AND one additional effective barrier method (e.g. latex condom, diaphragm, cervical cap).  If hormonal or IUD contraception is medically contraindicated, another highly effective method or two barrier methods must be used at the same time.</div>
<div class="sdl4">  -Pregnancy surveillance:</div>
<div class="sdl4">  -Patient must have a negative in office pregnancy test sensitive to within 50 mIU/mL (serum or urine) within 24 hours of beginning thalidomide even if continuous abstinence is the preferred method of birth control.</div>
<div class="sdl4">  -A pregnancy test must be performed weekly during the first 4 weeks of therapy and repeated monthly for patients with regular menses or every 2 weeks for patients with irregular menses </div>
<div class="sdl4">  -Negative pregnancy tests are valid for only 7 days.</div>
<div class="sdl4">  -If irregular bleeding or skipped menses, pregnancy test should be performed and pregnancy counseling given.</div>
<div class="sdl4">  -If pregnancy occurs during treatment, thalidomide must be immediately discontinued.  Any suspected lethal exposure must be reported immediately to Celgene Customer Care Center at 1-888-423-5346, and the patient referred to an OB/GYN experienced in reproductive toxicity for further evaluation and counseling.</div>
<div class="sdl4">  </div>
<div class="sdl4">  -Patient (or legally authorized representative) must be able to understand and willing to sign a written informed consent document.</div>
<div class="sdl4">  </div>
<div class="sdl4">  </div>
<div class="sdl4">  Exclusion Criteria:</div>
<div class="sdl4">  </div>
<div class="sdl4">  -Patient must not have any active, uncontrolled cardiac, hepatic, renal, or psychiatric disease defined as &amp;#8805; grade 3 based on NCI Common Terminology Criteria for Adverse Events v4.0 (CTCAE).</div>
<div class="sdl4">  </div>
<div class="sdl4">  -Patient must not be receiving any other investigational agents.</div>
<div class="sdl4">  </div>
<div class="sdl4">  -Patient must not have any active infection or concurrent illness obscuring toxicity or dangerously altering drug metabolism.</div>
<div class="sdl4">  </div>
<div class="sdl4">  -Patient must not have any thromboembolic event (deep vein thrombosis or pulmonary embolism) less than 3 weeks prior to enrollment.</div>
<div class="sdl4">  </div>
<div class="sdl4">  -Patient must not have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to any of the agents used in the study.</div>
<div class="sdl4">  </div>
<div class="sdl4">  -Patient must not be pregnant or breastfeeding.</div>
<div class="sdl4">  </div>
<div class="sdl4">  Inclusion of Women and Minorities </div>
<div class="sdl4">  </div>
<div class="sdl4">  -Both men and women and members of all races and ethnic groups are eligible for this trial.</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/criteria&gt;</div>
<div class="sdl2 sds">&lt;healthy_volunteers&gt;</div>
<div class="sdl3">  No</div>
<div class="sdl2 sdz">&lt;/healthy_volunteers&gt;</div>
<div class="sdl2 sds">&lt;gender&gt;</div>
<div class="sdl3">  Both</div>
<div class="sdl2 sdz">&lt;/gender&gt;</div>
<div class="sdl2 sds">&lt;minimum_age&gt;</div>
<div class="sdl3">  5 Years</div>
<div class="sdl2 sdz">&lt;/minimum_age&gt;</div>
<div class="sdl2 sds">&lt;maximum_age&gt;</div>
<div class="sdl3">  21 Years</div>
<div class="sdl2 sdz">&lt;/maximum_age&gt;</div>
<div class="sdl1 sdz">&lt;/eligibility&gt;</div>
<div class="sdl1 sds">&lt;investigator&gt;</div>
<div class="sdl2 sds">&lt;role&gt;</div>
<div class="sdl3">  Principal Investigator</div>
<div class="sdl2 sdz">&lt;/role&gt;</div>
<div class="sdl2 sds">&lt;name&gt;</div>
<div class="sdl3">  Lisa Madden, M.D.</div>
<div class="sdl2 sdz">&lt;/name&gt;</div>
<div class="sdl2 sds">&lt;affiliation&gt;</div>
<div class="sdl3 sds">&lt;agency&gt;</div>
<div class="sdl4">  Washington University School of Medicine</div>
<div class="sdl3 sdz">&lt;/agency&gt;</div>
<div class="sdl2 sdz">&lt;/affiliation&gt;</div>
<div class="sdl1 sdz">&lt;/investigator&gt;</div>
<div class="sdl1 sds">&lt;see_also&gt;</div>
<div class="sdl2 sds">&lt;annotation&gt;</div>
<div class="sdl3 sds">&lt;textblock&gt;</div>
<div class="sdl4">  Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine</div>
<div class="sdl3 sdz">&lt;/textblock&gt;</div>
<div class="sdl2 sdz">&lt;/annotation&gt;</div>
<div class="sdl2 sds">&lt;url&gt;</div>
<div class="sdl3">  http://www.siteman.wustl.edu</div>
<div class="sdl2 sdz">&lt;/url&gt;</div>
<div class="sdl1 sdz">&lt;/see_also&gt;</div>
<div class="sdl1 sds">&lt;keyword&gt;</div>
<div class="sdl2">  Glioma includes ependymoma and medulloblastoma</div>
<div class="sdl1 sdz">&lt;/keyword&gt;</div>
<div class="sdl1 sds">&lt;initial_release_date&gt;</div>
<div class="sdl2">  2012-07-30</div>
<div class="sdl1 sdz">&lt;/initial_release_date&gt;</div>
</div><div class="sdl1 sds">&lt;last_release_date&gt;</div>
</td>
</tr>
<tr class="sdiff-chg" id="sdiff-chunk-m15"><td class="sdiff-h">15</td>
<td class="sdiff-a"><div class="sdl2"><span class="sdwc">2012-10-29</span> </div>
</td>
<td class="sdiff-b"><div class="sdl2"><span class="sdwc">2013-01-24</span> </div>
</td>
</tr>
<tr class="sdiff-unc" id="sdiff-chunk-m16"><td class="sdiff-h">16</td>
<td class="sdiff-a"><img id="sdiff-collapse-m423A-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-m423&#39;)" style="display:none" /><img id="sdiff-collapse-m423A-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m423&#39;)" style="display:none" /><div class="sdl1 sdz">&lt;/last_release_date&gt;</div>
<div id="sdiff-collapse-m423A-cdiv" class="sdiff-collapsed" title="The middle 4 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m423&#39;)" style="display:none"></div><div id="sdiff-collapse-m423A-ediv" class="sdiff-expanded"><div class="sdl1 sds">&lt;init_disposition_release_date&gt;</div>
<div class="sdl1 sdz">&lt;/init_disposition_release_date&gt;</div>
<div class="sdl1 sds">&lt;init_results_release_date&gt;</div>
<div class="sdl1 sdz">&lt;/init_results_release_date&gt;</div>
</div><div class="sdl0 sdz">&lt;/clinical_study&gt;</div>
</td>
<td class="sdiff-b"><img id="sdiff-collapse-m423B-cimg" class="sdiff-collapse" title="Hide most of the text in this chunk of XML" src="/archive/collapse.gif" alt="[-]" onclick="SDiffCollapseCRID(&#39;sdiff-collapse-m423&#39;)" style="display:none" /><img id="sdiff-collapse-m423B-eimg" class="sdiff-expand" title="Show the hidden text in this chunk of XML" src="/archive/expand.gif" alt="[+]" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m423&#39;)" style="display:none" /><div class="sdl1 sdz">&lt;/last_release_date&gt;</div>
<div id="sdiff-collapse-m423B-cdiv" class="sdiff-collapsed" title="The middle 4 lines of XML in this chunk have been hidden for clarity" onclick="SDiffExpandCRID(&#39;sdiff-collapse-m423&#39;)" style="display:none"></div><div id="sdiff-collapse-m423B-ediv" class="sdiff-expanded"><div class="sdl1 sds">&lt;init_disposition_release_date&gt;</div>
<div class="sdl1 sdz">&lt;/init_disposition_release_date&gt;</div>
<div class="sdl1 sds">&lt;init_results_release_date&gt;</div>
<div class="sdl1 sdz">&lt;/init_results_release_date&gt;</div>
</div><div class="sdl0 sdz">&lt;/clinical_study&gt;</div>
</td>
</tr>

</table></div></form><div class="navBottom"><div class="navBottomLine" style="background-image: url(/archive/ctgov_logo_ttm.gif)">&#160;</div><div class="navBottomLinks">&#160;</div></div><script>
SDiffDeclareUnchCRID('sdiff-collapse-f0');
SDiffDeclareUnchCRID('sdiff-collapse-f135');
SDiffDeclareUnchCRID('sdiff-collapse-f176');
SDiffDeclareUnchCRID('sdiff-collapse-f411');
SDiffDeclareUnchCRID('sdiff-collapse-f521');
SDiffDeclareUnchCRID('sdiff-collapse-f66');
SDiffDeclareUnchCRID('sdiff-collapse-f71');
SDiffDeclareUnchCRID('sdiff-collapse-f78');
SDiffDeclareUnchCRID('sdiff-collapse-f85');
SDiffDeclareUnchCRID('sdiff-collapse-m0');
SDiffDeclareUnchCRID('sdiff-collapse-m135');
SDiffDeclareUnchCRID('sdiff-collapse-m176');
SDiffDeclareUnchCRID('sdiff-collapse-m423');
SDiffDeclareUnchCRID('sdiff-collapse-m66');
SDiffDeclareUnchCRID('sdiff-collapse-m71');
SDiffDeclareUnchCRID('sdiff-collapse-m78');
SDiffDeclareUnchCRID('sdiff-collapse-m85');
SDiffInit();
</script></body></html>